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I.

Abstract
This thesis presents the development of a Modified Aggregate Feature Commonality Index

(MAFCI) for analyzing information on medical labels, building on the Aggregate Feature Commonality
Index (AFCI) created by Shooter and Cohen [1]. The purpose of the MAFCI is to measure the
commonality of a set of manufacturers’ labels with minimal influence from non-essential features. Both
the AFCI and the MAFCI are applied to prescription drug labels commonly used at the Geisinger Medical
Center at Danville, PA. The difference between the MAFCI and AFCI is in the dissimilar weights placed on
essential features in the calculations for MAFCI versus equal weights placed on all features for the AFCI.
The MAFCI is the result of a conjoint analysis and Failure Modes and Effects Analysis (FMEA) with
abundant input from medical professionals at the Geisinger Medical Center. Conjoint analysis is used to
determine the weighing of features by visually presenting specially designed sample labels in survey
format to professionals at Geisinger. The results of the survey are then analyzed to yield weights for
specific features. The FMEA is then used support the results of the conjoint analysis. Differences
between the AFCI and MAFCI are then presented, showing more correlation between the MAFCI and the
commonality of the specific features identified.
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II.

Introduction
There is need for interoperability in the medical administration field. Millions of administrating

errors are made every year at hospitals and pharmacies nationally. There are estimates of 50 million total
mistakes annually in the United States, with about 3.3 million of the errors being medically significant [2].
This is due to a number of potential factors such as misreading labels, misprescribing, timing issues, and
incomplete documentation. A plethora of information needs to be on a medical container, but there isn’t
enough available area. Brand name, active ingredients, dosage and technical information are compacted
onto the label. With smaller packages, font sizes are decreased and are more difficult to read. The excess
amount of information results in label that is difficult to read, but contains all the necessary information.
A recent example that garnered a lot of media attention concerned the drug heparin, a drug used
to thin blood and flush out IVs. Actor Dennis Quaid’s newborn twins were accidentally given an overdose
of the drug, and were placed into intensive care for the overdose. While the twins were able to recover,
other cases of heparin overdose did not end well. In order to draw attention to the issue, Quaid filed a
lawsuit against Baxter Healthcare Corp (the manufacturer) instead of the hospital, stating that the error
was the result of insufficient labeling rather than negligence of the hospital [3]. Due to the media
attention, the FDA passed new guidelines in May 2013 and implemented a mandate requiring a new set
of information to appear on heparin vials. However, instead of covering a wide range of drugs in the
mandate, only labeling for heparin was specified. The changes are shown in Figure 1.

Figure 1: New and old heparin respectively, both with the same concentration and overall dose
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The majority of the proposed work will be done in conjunction with staff at Geisinger Medical
Center in Danville. Funding for this project comes from the Bucknell and Geisinger Research Initiative
(BGRI), which also established a means of contacting Dean Parry, the Director of Clinical Programs at
Geisinger. The pharmacy system implemented at the Danville center will also be implemented across the
Geisinger Health System. Medical supplies and internal labels that will be reviewed are ordered from
suppliers and manufacturers that are used nationally by other hospitals. A generic drug will often have
several suppliers, and inventory is often determined by availability of specific dosages at the time of order.
[4]
Recent barcode implementation at Geisinger Medical Center has dramatically reduced the
administrative errors associated with misreading medical labels [4]. Every container is scanned when it is
stocked at the pharmacy, significantly reducing errors at the source. After repackaging for a specific
patient, the drug is barcoded again and sent to the patient. Before administering, the drug is scanned and
confirmed to be the right drug for the patient. Because the system is networked, any changes to the
Medication Administration Record (MAR) would show up right away and an incorrectly ordered or
prepared drug can be stopped.
Nurses can still override the results from the scanner. This is because the scanner has issues trying
to read barcodes on non-planar surfaces (about 6% of the time) [4]. In case of emergency, this would
prevent holdup if the scanner can’t read the barcode. In other cases, the nurse can still decide not to
administer a drug based on professional judgment and the patient’s MAR. The barcode system at
Geisinger is not capable of catching excess dosage after multiple MAR entries. In these situations, the
printed drug information is critical to the nurse’s decision making process. This tracking system also allows
for more comprehensive data collection on errors, as all administration is recorded electronically.
In order to reduce error and maintain a contingency system, a metric needs to be developed that
measures the accessibility of crucial information on a label. Tallman lettering, icons, and color are some
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ways that companies attempt to differentiate their products, but formatting is inconsistent across
manufacturers. The information on drug packages is still necessary in the event of a network downtime
such as updates, crashes, or maintenance.
Work done by Cohen and Shooter is the starting point of this work. They created the Feature
Occurrence Commonality Index (FOCI), Feature Area Commonality Index (FACI), and the Feature Location
Commonality Index (FLCI). These measures relate the occurrences, areas, and locations of features on
product packages on a zero to one scale. This information is useful in finding trends in commonality and
errors related to drug selection for off-the-shelf drugs such as Tylenol Triaminic, and Dulcolax [5]. The
same measures could be modified for in-hospital labels and pharmaceutical labels, but the users are
inherently different. The purpose of the boxes on store shelves is to catch consumers’ attention whereas
the packages on pharmacy shelves are meant to convey technical information.
The metric needs to incorporate input from several different fields. Most important is input from
the pharmacy department on how the information is being utilized. Knowledge from a psychology and
advertising perspective is also important, as it is vital to understand the reasoning behind the way labels
are currently laid out. A human factors analysis is also necessary to develop a metric that can take human
limitations into account, including analysis from a human perception standpoint. Current government
regulations is also necessary, as a proposed metric that violates existing standards will not be acceptable.
A Venn diagram was created to illustrate the combination of factors that influences the development of
this metric (Figure 2).
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Figure 2: Venn Diagram of Various Disciplines and Players involved

A.

Project Goal
The goal of the project is to develop a metric to measure the salience of information presented

on medical packages used within a hospital. Methods such as conjoint analysis, FMEA, and Cognitive Task
Analysis (CTA) [6] will be used to determine the most important information and the results will be utilized
in the development of the metric. The system at Geisinger Medical Center in Danville will be used as the
primary case. The project will be successful if a new metric is developed that emphasizes the commonality
of important features on labels, and a potential label layout is proposed.

B.

Literature Review
A literature review of current practices was conducted. The majority of the search was focused

on developments within the past 4 years as a comprehensive review was conducted on this topic in the
previous iteration of the project [5]. The review will first clarify medical errors in a general sense to present
a grounding of the problem. Related topics and applications in engineering, psychology, and medicine will
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be inspected next. Finally a review of federal and private organizations related to the industry will be
presented.

1.

Medical Errors
Errors in medical application can be organized into two general categories, factual (or knowledge)

and action based [7]. Factual errors are made based on incomplete information surrounding drugs or
patients. This type of error can occur anywhere along the flow of the drug from the manufacturer to the
patient. The other category of errors is action based. This type of error could result from misreading a
label, delaying administration, or administering to the wrong patient. Action and factual based errors have
no effect on the patient in some cases, while others lead to an adverse drug event (ADE).
The most common knowledge based error comes from an error in ordering the prescription,
about 50% of all errors nationally [8]. Within this subset of mistakes, improper dosage is the most
common. A number of issues could lead to this error. Simply not knowing the proper dosage is technically
possible, especially with an uncommonly used drug. In addition, misreading the time stamps on test
results could lead to over-prescribing of a drug. Finally, confusing the name of the drug either in spelling
or actual name is possible.
Another subset of factual errors that could lead to an ADE is unpreventable. If a patient has an
unknown allergy, it unlikely to be caught until the drug has been administered. Even if the allergy is known
to the patient, the care providers may not be aware of the allergies due to miscommunication or
emergency situations. There is little that can be done to find these unknown allergies prior to
administering the drug itself. In addition, if the patient fails to list all drugs that he or she is taking,
unknown reactions could occur with a hospital administered drug.
Several inherent backups are built into medical prescription process to bolster the doctor’s
knowledge. Computerized medical administration record (MAR) is a record of times and dosages of all
drugs given to a patient. If a doctor attempts to prescribe too high a dose, the system will warn the
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prescriber of the error [9]. In addition, some newer systems will also refer to previous prescriptions to
ensure no overdoses occur. Computerizing the MAR also eliminates issues with messy handwriting that is
known to cause confusion when filling out the correct drug.

Figure 3: Sample MAR. Paper and Electronic respectively

Despite these fail-safes, errors can still occur. There have been several documented cases of the
doctor failing to fully inspect the MAR, especially after a shift change [8]. The dosage check in the program
also doesn’t catch repeat medications, something often used in therapies. In the case study from Horsky
[10], two different doctors prescribed almost equal amounts of KI to a patient, effectively doubling the
dose. This error occurred after a shift change, and came from the fact that the MAR displayed the repeat
dosage from the previous doctor but failed to warn the new doctor of the repeated dose on queue.
In a similar case study from the same article [8], the patient was prescribed additional drugs
because the time stamp from a blood test wasn’t read. The first doctors prescribed medication to even
out levels of calcium in the patient. After the treatment, a second blood test was ordered. However the
first doctor was off shift before the results came back. The second doctor saw the blood test results from
several hours earlier and ordered the same treatment.
Partially mentioned in the two case studies above, shift changes are times when errors are most
likely to occur [11]. At the end of a shift, staff are often tired after working for more than 12 hours. The
new shift coming in is unaware of the specifics of patient needs, aside from what is written down on the
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MAR. Errors that occur during this time period can usually be attributed to factual errors, when the passing
of knowledge to the new shift is incomplete. In addition, hospitals are often understaffed. This could lead
to not having enough time to thoroughly review the MAR from the previous shifts before rushing off to
the next patient. There is no standardized MAR; systems vary across hospitals. Some lack the ability to
make specific notes, such as recommended route of administration. Occasionally patients will respond
better to treatment through a specific method of delivery (or adversely to the default method).
The other type category of error is action based, accounting for the other 50% of errors. However,
these can be further broken down in to administering (25%), dispensing (14%), and transcription (11%)
[7]. Mistakes from pressing the wrong button, picking up the wrong dosage, or improperly stocking the
shelves are all categorized under this category. An incident occurred recently when a pharmacist
misplaced two drugs, methylphenidate and methadone [12]. A child was given the drug that had been
dispensed into the wrong bottle, and required treatment at an emergency room. The similarity of drug
names often causes this kind of administrative error. The heparin instance mentioned in the introduction
is another case of action based error. The nurse misread the prescription and picked the wrong dosage of
heparin to administer. Another example of an action error is a failure to refrigerate, causing the drug to
deteriorate prior to administration.
A common dispensing error occurs when nurses dispense drugs to the wrong patient. This is more
likely to occur in a shared-room situation, especially when drugs arrive at the same time [8]. A failure to
double check the MAR or getting the patients confused can lead to this error, especially during a shift
change.

2.

Engineering
A few methods commonly used in engineering were researched. Failure Mode and Effects Analysis

(FMEA), product family planning, conjoint analysis, and Cognitive Task Analysis (CTA) were studied in
hopes of using these methods for development of the metric.
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Attempting to predict the outcomes of failure will also be helpful in determining the factors that
influence the metric. Research into FMEA was conducted in conjunction with medical errors. The
Department of Veteran Affairs has developed a specialized version of FMEA, Healthcare FMEA (HFMEA).
It is essentially a version of FMEA streamlined for use in medical field, with certain factors such as “risk
priority number” removed in favor of a hazard score [13].
Product family planning is another engineering method that could be applied to preventing
medical errors. Some drugs stocked in a pharmacy are effectively product families with differing doses.
The general advantage to creating and maintaining a product family is reduction of manufacturing costs
while producing a variety of products. Reduction in manufacturing cost is achieved using common
components across a family, and thus simplifying the design. The manufacturer that offered more product
variability was able to fulfill more customer requirements and therefore sell more product.
Platforming a product is useful in increasing product line lifetime, decreasing lead time of a new
design, and ease of repair [14]. However this is not appropriate for every case. Careful initial planning is
required for an effective product platform, and this leads to higher initial costs. If the planned life of the
product line is short, it makes little sense to design a product platform. Additionally, if too many
components are shared across a platform, products will begin to compete with each other, reducing
revenue.
Another use of a product platform is to quickly saturate a market. Producing a large number of
products that attempts to fill all niches could increase market share in that field. Competitors not utilizing
product platforms would not be able to keep costs low while maintaining variety [14]. Thus a company
may lose money in the short term, but will gain an advantage over competitors over time due to increased
market share and recognition.
Mass customization is a useful concept that stems from producing a product family. The
manufacturer produces a family that has limited variation, instead relying on other parties to tailor the
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product to meet specific customer needs. The method of production takes advantage of economies of
scale, but doesn’t lose out to competitors in terms of variety [15]. Alizon examines the Ford Model T [15],
which utilized mass customization to keep costs down and relied on other shops to customize the model
to customers’ needs. Doing so allowed Ford to expand variability in the car while keeping costs down,
allowing the company to grow. Drug companies operate in a similar manner; they don’t produce every
possible dosage. The packaging costs for such variability would outweigh the cost of the drug itself.
Instead, a set of generic doses are produced, and pharmacists mix the drug to the proper dose.
Several metrics have been developed to measure commonality and differentiability in a product
family. The Commonality Differentiation Index (CDI) was developed by Cohen [1] as a way to measure the
amount commonality that product platform exhibited. In addition to common components, functions and
aesthetics were considered in the index. Several examinations were done by dissecting power tool families
from various manufactures [16]. As with many metrics, no specific recommendations were made on what
number was considered “good.” Too much commonality could lead to low-end products competing with
higher-end products, whereas too much differentiation could break platform cohesion and increase
manufacturing costs.
Stemming from this index are the FACI, FLCI, and FOCI that were developed by Shooter and Cohen
in the previous iteration of this project. These metrics considered the location of features such as brand
name, active ingredient, dosage, etc. found on off-the-shelf drugs [5]. The location and area were also
normalized and calculated as part of the index. This leads to a very direct metric on the commonality of
the layouts. Dulcolax, one of the drugs studied, had one of the lowest scores in all three indexes, and it is
known to be have one of the highest error rates. However, as only a few brands were studied, there isn’t
enough data to draw a correlation between the index and error rates.
Several other metrics exist that relate commonality of a product family. The Comprehensive
Metric for Commonality [17] and Heterogeneity Homogeneity Ratio [18] are methods of measuring
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commonality of parts and functions, with different equations for calculating the final index. The CMC
accounts for value added and has a modifier for comparison against competitors. A product family
evaluation graph is used to plot the outcomes and compare different families.
Conjoint analysis is a marketing research technique used to turn user preferences into suitable
numbers for engineering specifications. A simple survey or interview doesn’t necessarily result in useful
numbers, especially if a semantic scale is used [19]. In Orsborn and Cagan’s study, the dimensions of
several SUVs were quantified in order to capture the form of each vehicle’s design. Several samples
representing SUV designs were generated based on interactions between the dimensions. The samples
were then compiled in a survey to garner consumer feedback. The results were analyzed to generate
utility functions which represented the consumer preferences for specific dimensions. For example, the
maximum of the utility function for distance between the cowl and front axle was 55.8 inches. This
indicates that consumers preferred the cowl to have close proximity with the axle. A similar process will
be applied to the medical labels to figure out user preference.
Cognitive task analysis is an interview process used to generate the thought process diagram of a
professional. The interview usually involves recounting of errors or specific events in order to figure out
how outcomes were reached. This interview process has helped senior meteorologists properly record
how they made correct unorthodox decisions [6]. The interview process is used to construct a process
diagram necessary for conducting a FMEA.

3.

Psychology
Considering the information from a purely technical sense isn’t enough to develop a

comprehensive metric. Input from the field of psychology is also necessary due to quirks in human
perception. People don’t always see things in an objective manner and are easily swayed by internal and
external factors.
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Brand name is one of the most important fields to consider when designing a packaging. Most
companies that sell off-the-shelf (OTC) drugs place special emphasis on brand name. Brand name
consistently scores highest in the FACI, FLCI, and FOCI index, indicating that the brand name is most
common across package labels [5]. This is simply due to the fact that a strong brand name is one of the
strongest marketing advantages a company has over competitors, especially if the same drug is available
as a generic. Tylenol and Dayquil are two examples of companies that have strong brand name recognition
and prominent placement.
Human memory is also important to consider. On average, people have a limited working
memory, limited to about 7 blocks of information [20]. Each block is a set of information that is easily
remembered. For example IT IS RAINING is easier to remember than GIIT NNIIAR. Clustering allows for
more information to be remembered.
Memory is also largely a reconstructive process. Someone who has lost the ability to create new
long-term memories will draw different conclusions about finding foil in his pocket, even if the scenario is
recreated exactly. In one instance, the patient thought it was Valentine’s Day. When asked about the foil
later in the day, he assumed it was Easter [21].
People are also prone to confirmation bias and inattentional blindness. Confirmation bias occurs
when a person sees what he wants to see, but may fail to realize such a bias is occurring. In terms of
medical errors, look-alike, sound-alike drugs of problematic because they are easy to confuse.
Inattentional blindness occurs when people are focused on another task. New stimuli are ignored, even if
the brain processes the event (confirmed using eye tracking). In a study conducted by Mack [22],
participants were asked to count the number of times a ball was passed in a group of people.
Approximately 50% of participants failed to notice a man in a gorilla suit walking through the group (Figure
4) [22].
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Figure 4: Inattentional blindness, gorilla in the middle of field of view [22]

Studies show that information on packages is often ignored, even if it is relatively prominent.
Shoppers almost never consider the unit price, and rarely check the expiration date. Others in the study
recognized these figures but didn’t care [23]. The presence of information does not indicate
comprehension.

4.

Medical Technology Implementations
There have been several technological innovations in the field of medical administration. Fully

networked programs and systems reduce the number of errors. Barcodes on all drug orders at Geisinger
Health Center has prevented patient mix-up and greatly reduced the number of mislabeled drugs that
come out of the pharmacy [4]. Nurses can still override barcodes at Geisinger because barcode reader
errors still occur.
Radio Frequency Identification (RFID) tags can also be used to track drugs and ensure it goes to
the right patient. The RFID tags can also store more information, meaning network coverage isn’t
necessary for it to function. However, theses tags are more expensive than barcodes and also require
special readers. They are useful for keeping track of inventory, including any equipment that gets moved
around. In a few hospitals where trials were set up, the response from the staff was negative [24]. They
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complained of a Big Brother-like system where everyone’s actions were excessively monitored, and an
inordinate amount of maintenance was required to keep the system running.
Smart pumps have made some headway in preventing administration errors. The pumps are
directly linked to the pharmacy, where a pharmacist can regulate the delivery rates directly [9].
Implementing this system removes another person along the administration process that could make an
error; the nurse doesn’t need to set the infusion rate. These pumps require network access in order to
function properly but can be set for more complex drug delivery.
A data monitoring system is also being implemented at some hospitals. Clinical Decision Support
(CDS) can be tailored to each hospital. These systems act as a backup and checks doctors’ orders as they
are input into the system. This also allows for a clear electronic record of all orders, making tracking easier.
The Computerized Physician Order Entry (CPOE) is like the name implies. Combining these two systems
would prevent a large percentage of prescription error. Due to the electronic nature of these orders, it
now becomes possible for a pharmacist to check the orders without slowing down the process [9].

5.

Government and Organizations
There are several organization in charge of reporting errors and setting standards. Most

prominent is the Food and Drug Administration (FDA). It regulates how and when drugs appear on the
market. Twenty years after the initial patent of a drug, the active ingredient is no longer under patent and
other companies can begin producing it. These generic drugs also need to be approved by the FDA, though
the process for approval is much shorter. The active ingredient has already been on the market for several
years and the focus of the approval process is on the quality of the generic drug. Regulations indicate that
the drug must have the same absorbency rate (+ 3%) and have a different physical appearance. The FDA
also has a project to implement Tall Man lettering on drug names for look-alike, sound-alike drugs. Figure
5 show some examples of Tall Man lettering used to differentiate these drugs.
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Figure 5: Examples of Tall Man lettering

Other organizations keep statistics and report on errors. The Institute for Safe Medication Practices (ISMP)
and the National Coordinating Council for Medication Error Reporting and Prevention (NCCMERP) keep
track of these medication errors. Statistics of specific drugs is available on request.

6.

Thesis Organization
The thesis will be organized based on topic. Section III describes the methodology and results of

the FCI analysis of several pharmacy drug labels identified by Dr. Parry. This is the baseline for the
development of the new metric. Section IV describes the conjoint analysis of heparin labels to
determine the relative importance of label features. The details of the conjoint analysis and the
development and results of several surveys are also covered in this section. A proposed format for
heparin labels is also included in this section. Section V contains details on the FMEA of labels at
Geisinger. The results of several interviews are condensed into a process diagram, and the features with
the highest risk to the patient are identified. Section VI details the new metric, and its application to the
labels analyzed in Section III. The conclusion is located in Section VII, as well as potential applications of
the metric and future work.
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III.

FCI Analysis
The Feature Commonality Index (FCI) is a normalized measure of how similarly a feature is sized

and located on a label [1]. A high Feature Area Commonality Index (FACI) indicates that the feature has
consistent size, and a high Feature Location Commonality Index (FLCI) indicates the feature is located in
the same place across multiple labels. Conversely, a low FACI and FLCI indicates that the feature is
differently sized and located, respectively. The index takes all features on a label or package into account
when calculating the FACI and FLCI. An aggregate of FACI and FLCI for all features is referred to as the
AFACI and AFLCI respectively. The evaluation of this index is beyond the scope of this thesis. A study by
Cho and Miller has shown that a lower rating (less commonality) leads to higher selection times and more
errors when choosing OTC drugs [25].

A.

Methodology
I removed the labels for heparin and various forms of insulin from their vials and digitally scanned

for easier measurements. The labels were printed on laminated paper and no visible warping was
observed after removing them from the vials. Several labels were scanned at the same time in color at
300 points per inch. They were then cropped to form separate files for each label. Each image was rotated
so that the letters were aligned to the horizontal axis. Some smaller images were scaled, but the aspect
ratio was maintained. A complete set of images appears in Appendix A.
The first step to the FCI analysis is to generate a list of features that appear on the labels. This
process was time consuming due to the multitude of features on the labels and variations in the
manufacturers’ labeling schemes.
The next step was to measure the location and area of each of the features with respect to the
bottom left of the label. The original method used in Cohen’s study was to use a ruler and measure the
area and the center position of each of the features. The study this time utilized two different methods to
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obtain position and size data for all the features. In Method 1, the images were imported into
Solidworks™. The bottom left of the label was aligned with the default origin in the program. The images
were processed using the sketch picture function in Solidworks™. Rectangles were drawn around each of
the features. Every shape and point in a Solidworks™ sketch contains coordinates relative to the origin.
The resulting sketch is shown in Figure 6. Calculating the area and location of the features was fairly simple
once all the rectangles were drawn.

Figure 6: Using Solidworks™ for calculating the area and the location of features. The origin is at the bottom left of the label,
and the red circle highlights the centroid of a feature at the x and y parameters displayed.

Method 2 used a script written in MATLAB. This script loaded the images in a figure and then
requested user input for two points to define each feature. These two points were the opposite corners
of a rectangle that enclosed the feature. A sample of the resulting image is shown below in Figure 7. The
script then calculated and recorded the location of the centroid and the area.
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Figure 7: Using MATLAB to calculate the area and locations of features. The MATLAB script takes care of all AFACI and AFLCI
calculations.

Finally the data was processed utilizing another custom MATLAB script to calculate the FACI and
FLCI from the recorded location and size data. The code for calculating the AFACI and AFLCI is written in
MATLAB and can be found in Appendix B and C. The values were normalized based on the size of the
packages. FACI and FLCI are calculated based on the following equations from Cohen [1]:

𝑃𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛 𝐷𝑖𝑓𝑓 =

|𝐴̅−𝐴𝑗 |
̅ +𝐴
𝐴
𝑗

(

2

(1)

)

where 𝐴̅ is the mean and Aj is the instance value. And finally, FACI is
𝐹𝐴𝐶𝐼 = 1 − 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑃𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛 𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒

(2)

The FLCI is calculated using:

𝑑𝑗 = √(𝑥̅ − 𝑥𝑗 )2 + (𝑦̅ − 𝑦𝑗 )2
𝑑𝑎𝑣𝑔 =

∑𝑃
𝑗=1 𝑑𝑗
𝑃∗𝑑𝑚𝑎𝑥

where dmax is the calculated maximum possible distance on the package, and P is the total number of

(3)

(4)
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package instances with that feature. The Feature Location Commonality Index is then calculated as:
𝐹𝐿𝐶𝐼 = 1 − 2 ∗ 𝑑𝑎𝑣𝑔

(5)

The FACI and FLCI are measures of the commonality of a feature across all the labels. Averaging the values
for all of the features gives the Aggregate Feature Area Commonality Index (AFACI) and Aggregate Feature
Location Commonality Index (AFLCI). The MATLAB code for these calculations can be found in Appendix 0
and C. The methodology using MATLAB required much less time compared to the Solidworks™ method,
and could potentially be used by someone no familiar with the software.

B.

Results

1.

Heparin
Table 1 shows the AFACI and AFLCI of heparin labels from all manufactures used at Geisinger (APP,

Sagent, Pfizer, and Medefil). Certain features, like brand name (BN), active ingredient (AI), concentration
(C), and volume (V) are isolated and are also shown in the table. BN+AI almost always appear together
and are distinctly separated from the rest of the label through unique formatting. This is true for
concentration and volume as well. Figure 8 shows a heparin label reproduced in actual scale. The AI + BN,
concentration, and volume are highlighted in red. The rectangle shows the area used to calculate the FACI,
and the centroid of the rectangle is the point used to calculate the FLCI.

(BN + AI)
(C)
(V)
Figure 8: APP Heparin Label in real life scale. The important features are labeled.
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Table 1: Heparin AFCI for all manufacturers

All
BN+AI
C+V
Other

AFACI
0.58
0.47
0.36
0.60

AFLCI
0.61
0.67
0.52
0.62

The results from this analysis show an area of the AFACI and AFLCI that needs improvement. The AFACI
for brand name, active ingredient, concentration, and volume are much lower than the AFACI for all
features. However, these features were determined to be more important in a professional’s selection
process than the other features. (This will be explained in further detail in Section IV). The AFLCI for the
BN and AI are higher than the AFLCI for all features, but the AFLCI for concentration and volume are lower
than the index for all features. This indicates that the most important features’ location and area vary
more than the other features.
Table 2: Heparin AFCI for Sagent

All
BN+AI
C+V
Other

AFACI
0.64
0.95
0.67
0.63

AFLCI
0.79
0.64
0.66
0.81

A similar trend is observed when the data is broken up by manufacturer. The results of the
commonality analysis from the manufacturer Sagent are in
Table 2. The vials from the manufacturer Sagent come in three different sizes: two 10 mL, one 1 mL, and
two 2 mL. A quick visual inspection shows that the layout changes with the vial size (Figure 9). The
orientation of BN+AI, concentration, and volume for the 10 mL vial is different than the others, and the 1
mL label has different formatting for the volume and concentration. The area of the BN+AI are much
more common than that of other features. However, the locations of the more important features vary
more than other features.
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Figure 9: Sagent labels. The bottom right and bottom labels are post FDA mandate. The others are pre-mandate. (not to scale
due to size differences between labels)

The manufacturer APP has greater overall commonality compared to Sagent, with much higher
commonality in location (refer to Table 3 below). The vials from this manufacturer come in three different
sizes; one 10 mL, one 1 mL, and two 5 mL. A quick comparison shows that the general layout doesn’t
change much between different vial sizes (Figure 10). This is much different than the labels for Sagent,
which change orientation when vial size increases. The area and location of the concentration and volume
vary more than all other features. The AFACI for BN and AI are higher than the overall index, while the
AFLCI is about the same. The AFACI and AFLCI are higher than the average of the 4 more important
features.

Table 3: Heparin AFCI for APP

All
BN+AI
C+V
Other

AFACI
0.78
0.81
0.63
0.80

AFLCI
0.91
0.92
0.84
0.92
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Figure 10: All APP labels. The top right label is post FDA mandate. The others are pre mandate

Medefil has the highest commonality of all three manufacturers (refer to Table 4 below). Medefil
produces syringes rather than vials, and both are 5 mL. A quick comparison shows that the general layout
doesn’t change (Figure 11). The labels are from pre and post FDA mandate, and the lower AFACI for the
concentration and volume reflects this change.

Table 4: Heparin AFCI for Medefil

All
BN+AI
C+V
Other

AFACI
0.93
0.99
0.86
0.94

AFLCI
0.95
0.86
0.90
0.97

Figure 11: All Medefil labels. The top right label is post FDA mandate. The others are pre mandate
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Table 5 has the results of the analysis for vials only. The commonality should increase if the
syringes are taken out of the AFACI and AFLCI analysis because the general layout of the syringe labels
differs a lot from that of the vials. This trend is true for the overall AFLCI and AFLCI. The indexes are still
lower compared to the indexes for individual manufactures due to the varying formats.

Table 5: Heparin AFCI for all vials

All
BN+AI
C+V
Other

AFACI
0.62
0.67
0.47
0.63

AFLCI
0.65
0.63
0.63
0.65

Table 6 and Table 7 show the results of the analysis preformed on labels before and after a FDA
mandate to change the format of concentration info. The analysis includes all container types (vials and
syringes). In general, the commonality of the location increased after the mandate. However, the area
commonality for the four important features decreased as a result. The overall AFACI is a bit misleading
in terms of showing an improvement from the FDA mandate. See Figure 12 for both before and after
mandate labels.

Figure 12: Comparison of Before FDA Mandate (left) and After FDA Mandate (right)
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Table 6: Heparin AFCI for labels before FDA mandate

All
BN+AI
C+V
Other

AFACI
0.60
0.50
0.44
0.61

AFLCI
0.57
0.60
0.52
0.57

Table 7: Heparin AFCI for labels after FDA mandate

All
BN+AI
C+V
Other

AFACI
0.63
0.41
0.37
0.65

AFLCI
0.63
0.72
0.55
0.63

The sizes of the containers also has an effect on the AFACI and AFLCI. Sagent changes the
formatting on larger vials, rotating some features. This changes the location of the centroid, and the effect
is shown in a lower FLCI when compared to the other manufacturers. The orientation could potentially be
included in future commonality measures if more instances of varying orientations were exhibited in the
sample set.
The AFACI and AFLCI for individual manufacturer are higher than that of a combined index. This
shows a lack of unified formatting for labels despite the FDA mandating a change in the labeling system.
Many of the cases show that the AFACI and AFLCI for BN, AI, concentration, and volume are lower than
the overall index. There is a need to improve the AFACI and AFLCI to reflect the importance of these
features when taking a vial or syringe out of storage. These features are among the list of important
features identified by the conjoint analysis in Section IV and the FMEA in Section V.

2.

Insulin
Table 8 shows the AFACI and AFLCI of Insulin labels from all manufactures used at Geisinger (Lilly,

Novo-Nordisk, and Sanofi-Aventis). Brand name (BN), active ingredient (AI), concentration (C), and volume
(V) are isolated and are also shown in the tables below.
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(BN + AI)
(C)
(V)
Figure 13: Insulin labels from Novo and Sanofi (actual size).

Table 8: Insulin AFCI for all manufacturers

All
BN+AI
C+V
Other

AFACI
0.76
0.58
0.76
0.77

AFLCI
0.59
0.65
0.59
0.58

The location of features across the insulin manufactures varies much more than those of heparin
due to the different formats. Figure 13 and Figure 14 show the varying formats from different
manufacturers that result in the low AFLCI. The sizes of the features are approximately the same despite
the different layouts, resulting in a high AFACI. The area of the BN and AI are very different and results in
a low AFACI for those features.
Table 9: Insulin AFCI for Lilly

All
BN+AI
C+V
Other

AFACI
0.81
0.56
0.88
0.82

AFLCI
0.76
0.82
0.75
0.75

A commonality analysis split by manufacturer can only be done on the Lilly labels because there
is only one sample from the other manufacturers. The results of the analysis can be found in Table 9.
Generally, the commonality is much higher, except for the size of the BN and AI features. This is due to
more text in the Humalog® Mix 75/25, which takes up much more of the label than the Humulin® and
Humalog® (Figure 14).
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(V)

(C)
(BN)
(AI)

Figure 14: Insulin labels from Lilly labels (actual size).

The commonality is greater within the same manufacturer when compared with the overall index,
similar to the trend observed in the heparin labels. The amount of text describing the active ingredient
varies depending on the drug and causes lower commonality of the area. For example “insulin lispro”,
“NPH human insulin isophane suspension”, “Insulin detemir”, and “insulin glargine” are the active
ingredients for the various vials of insulin. In contrast, heparin is always called “Heparin Sodium.” The
AFACI of BN+AI for insulin is generally 0.35 lower than that of heparin when separated by manufacturer.
The concentration and volume are much more common compared to those of heparin manufactures.
Again, this is due to the more consistent concentration and volumes for insulin versus heparin.
Concentration and volume for insulin is always in the same number of digits (100 units), while the heparin
values differ by up to two digits (500 vs 50,000 units).
Location measures for the insulin show a lower number, either in the overall set or by
manufacturer when compared to heparin. This is due to the variation in the overall organization of the
insulin labels; the insulin label has the BN+AI, concentration, and volume located in the right, center, and
left regions. In contrast, almost all of the heparin vial labels have these features located in the left region.
The AFLCI for concentration and volume of insulin (0.75) is lower versus the heparin manufacturers except
Sagent (0.66). This difference can be accounted for by the seemingly arbitrary change in orientation of
the concentration and volume in the larger Sagent vials. This difference isn’t well described by the AFLCI
of all features using the current calculations.
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3.

Tramadol
The available labels for tramadol are relative homogeneous. Differing from the previous drugs,

tramadol is a solid and is ingested rather than injected. The drug name is the equivalent to the AI+BN, and
the mass is equivalent to concentration and volume. Mylan is the only manufacturer for these labels. The
results of the FCI analysis can be found in Table 10.

Table 10: Tramadol AFCI for all labels.

All
Drug Name
Mass
Other

(A)FACI
0.78
0.81
0.84
0.76

(A)FLCI
0.86
0.97
0.86
0.83

The FACI and FLCI for the drug name and mass are higher than the aggregate index. There is more
variation in the other features, and drug name and mass remain consistent. The labels can be found in
Figure 15. The formatting is very consistent, with drug name appearing in the top center, and mass located
below it. The variation of the top label is due to the blister packaging type. The bottom three labels are
printed onto a flat paper and plastic cover. The overall AFACI and AFLCI are close to the average values of
drug name and mass. This is due to a lower number of other features, meaning drug name and mass have
more impact on the aggregate index.
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(AI)
(Mass)

Figure 15: All tramadol labels (actual size).

The overall AFACI of the tramadol is similar to APP (0.78) and Lilly (0.81). The AFACI of the AI+BN
is also the same for tramadol and APP (0.81), both of which are higher than the Lilly AFACI for AI+BN
(0.56). As previously discussed, this is due to a consistent name, whereas the insulin labels have a lot more
variety. The name is consistently located at the top center of the label, leading to an FCI of 0.97, the
highest of all examined labels. APP has the next highest AFACI for AI+BN at 0.92. These high values indicate
highly consistent formatting for the placement of the name. Visually comparing Figure 10 and Figure 15
shows that the drug name is very consistently placed for both of these manufacturers.
The FACI for the weight (0.84) is slightly less than that of insulin’s concentration and volume (0.88).
This is due to the consistency of units on the tramadol labels, which differ by at most one digit (50 vs 200
or 12.5). The FLCI for mass (0.86) is similar to that of APP (0.84). Both manufacturers have consistent
formatting, with no changes in orientation or overall format.

C.

Comparison with previous measures

1.

Tylenol, Dulcolax, and Thermaflu, Triaminic
A comparison of the labels of various manufacturers can be found in Table 11. Index numbers

for Tylenol, Triaminic, Thermaflu, Dulcolax are from Cohen [1]. The average aggregate commonality are
approximately the same for over the counter (OTC) and prescription drugs. The average AFACI and AFLCI
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for OTC drugs are 0.78 and 0.82 respectively, and the average AFACI and AFLCI for prescription drugs are
0.79 and 0.85 respectively.
Table 11: AFCI for various other over the counter drugs and pharmacy drugs

Tylenol®
Triaminic®
Theraflu®
Dulcolax®
Sagent
APP
Medefil
Lilly
Mylan

AFACI
0.72
0.876
0.80
0.71
0.64
0.78
0.93
0.81
0.78

AFLCI
0.79
0.90
0.83
0.765
0.79
0.91
0.95
0.76
0.86

There is no clear improvement of consistency between OTC and prescription drugs, though some
manufacturers such as Medefil, Lilly, and Mylan are above the average versus OTC drugs in terms of AFACI.
These manufacturers have relatively consistent size of all features. The AFLCI of APP, Medefil, and Mylan
are higher than the average of the OTC drugs, showing a greater consistency of locations for all features.
There are some inconsistencies when some feature commonality indexes are considered.
The AFACI of BN+AI for Lilly is significantly lower than the OTC average (0.56 vs 0.78), but the
AFACI of Sagent (0.95), APP (0.81), Medefil (0.99), and Mylan (0.81) remain more consistent than the
overall average of OTC drugs. Concentration and volume AFACI for Medefil (0.86), Lilly (0.88), and Mylan
(0.84) have above average values. Sagent and APP fall to well below average at 0.67 and 0.63 respectively.
AFLCI numbers are a bit more consistent, with Sagent and Lilly falling below the average, for overall and
individual FCI of drug name, concentration, and volume. APP, Medefil, and Mylan are above average for
these features.
AFACI and AFLCI may not give a clear picture when comparing different drugs with such a wide
range of numbers for the commonly used features. The aggregate doesn’t accurately represent the more
commonly used information. The features classified under “Other,” such as the manufacturer’s address
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or an “Rx” symbol, can increase the AFACI and AFLCI without really increasing the consistency of
commonly used features.

In the following sections of the thesis I will explore techniques for improving the commonality
indices. In the next section I employ a questionnaire with medical practitioners to determine their
preferences for the appearance of label information. The questionnaire will be developed using a
technique called Conjoint Analysis which presents alternative designs to determine user preference. This
approach will provide information that can improve the indices by adding appropriate weights to the
feature measures.
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IV.

Conjoint Analysis

A.

Background
There are several methods to determine aesthetic preferences of consumers. Surveys, focus

groups, and statistics are all ways determining what properties or designs appeal most to a customer.
However, these methods are not granular enough for determining specifications for the design because
they rely on a semantic scale (words rather than numbers). The design of the study is also difficult due to
different semantic scales for individuals. In traditional surveys with numerical ratings, most respondents
failed to utilize the entire range of responses [26]. “Strong” and “big” have varying connotations to
different people and limit the quality of data attainable from studies using them [19].
Conjoint analysis resolves this issue by presenting a questionnaire of sample designs with specific
feature attributes to the consumers or users. Careful design of the questionnaire and sample designs are
necessary for attaining useful data from the analysis. Each sample must have the proper attributes, and
each question must have the right combination of samples. The consumers then select the designs that
appeals to them. Analysis of these results show the influence of each feature on the consumers’ selection
process. In addition, the ideal specification of the feature can be determined by the results of the survey
created for the conjoint analysis [19].
The conjoint analysis is useful for a relatively small number of varying attributes. The number of
questions and sample designs required in the analysis increases exponentially with the number of
attributes in a design. There is a limit of approximately 30 attributes before the technique becomes too
numerically complex [27] and fatigues the interviewees. There are 30 features on a heparin label, and
multiple attributes for each label. Therefore, a method for reducing the number of attributes was
employed to simplify the analysis.
Statistical Analysis system (SAS) is commonly used in statistical analyses, offering built-in macros
for most functions used in statistics. Many of the specialized macros are based on work done at North
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Carolina State University in the 1970s, with project leaders Jim Goodnight and Jim Barr. Since then, it has
been commonly used by pharmaceutical and insurance companies [28]. The software was also
recommended by Professor S. Orsborn, a professor in the School of Management at Bucknell University,
for use with conjoint analysis.
Both surveys used in the conjoint analysis were approved by the Institutional Review Board (IRB).
The surveys were administered voluntarily, and posed no danger to the well-being of the participants.
Only medical professionals employed at Geisinger were asked to complete the survey, and only the
profession from each respondent is recorded. No other identifying information is kept. The responses
were stored electronically in a password-protected account.

B.

Preliminary Survey
The 11 most important features for selecting a drug were determined after consultation with Dr.

Dean Parry, RPh. In an attempt to further reduce the number of features, a preliminary survey was
administered to medical professionals at Geisinger (Appendix D). A traditional 1-10 scale was used in an
attempt to measure the importance of each feature, with 1 being unimportant, and 10 being very
important.
Twenty responses were received, with 6 responses from nurses, 4 from pharmacy technicians,
and 10 from pharmacists. The features and the rating of importance can be found in Table 12. The National
Drug Code (NDC) and source of the active ingredient were eliminated based on the overall ratings. The
barcode was an absolute necessity in the process of preparing the drug at Geisinger, so any rating greater
than 7 was kept.
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Table 12: List of features and ratings of importance. 10 indicating most important, 1 indicating least important

Brand Name
Active Ingredient
Concentration
Volume
Delivery Method
Storage Method
Barcode
Lot / Expiration
NDC
Warning Label
Source

Average
Ratings
8
9
9
8
9
8
8
9
6
8
5

To further decrease the number of features that will be varied in the conjoint analysis, several
similar features were paired together. Active ingredient and brand name were paired together because
they both describe what the vial contains, and sometimes refer to the same feature. Concentration and
volume were paired because both are related to the amount that was in the container. In addition, each
pair of features were always displayed next to each other with very little variation across the labels
examined. Finally, no variation in the barcode was possible, as size and style are fixed. The barcode was
kept in the sample designs, but it was not part of the conjoint analysis. Eleven independent features were
reduced to two pairs and four independent features:







1.

Brand Name + Active Ingredient
Concentration + Volume
Delivery Method
Storage Method
Lot/Expiration
Warning Label

Survey Improvements
The traditional 1-10 scale should not have been used, as respondents rarely use the entire scale

[26]. A fixed sum rating or ranking the features would be more appropriate if a similar survey is to be
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administered in the future. If importance of the features needed to add up to 100, the importance of each
feature would be clearer to the respondent and clearer in the data. The fixed sum forces the respondents
to think and actually weigh the relative importance instead of assigning high values to everything.
According to Ullman, any design with less than 30 requirements can use this method, but more than 30
questions will result in the respondent being unable to properly rate everything [26].

C.

Design of Survey

1.

Feature Factors and Levels
Specific factors or properties were then assigned to the six features identified from the

preliminary survey. The SAS macro %mktruns was used to confirm the proper number of samples
necessary for 100% efficient design [29]. The 100% efficiency indicates that there are enough relations
between the various factors to determine importance and preference. After several trials, the ideal
number of levels and factors was determined to be two factors at three levels, and eleven factors at two
levels. Inputting:
%𝑚𝑘𝑡𝑟𝑢𝑛𝑠(3 ∗∗ 2 2 ∗∗ 11);

(6)

confirms that 100% efficiency can be achieved with 36 samples. This layout of factors is not a full
factorial, meaning that not all possible combinations are accounted for. Instead, a fractional factorial
can be generated from these factors and levels. A fractional factorial with 100% efficiency can garner
the same information as a full factorial, but it utilizes the sparsity-of-effects principle to reduce the
number of combinations required [30].
For the BN+AI (Brand Name + Active Ingredient) pair, three factors were determined to be
important and easily varied (see Figure 16). Font style could be change between tall man, all capitalized,
or normal for the various samples. Tall man has been proposed as a potential way of differentiating drugs
to avoid medical errors. Normal and all capitalized are two styles currently being used by APP and Sagent
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respectively (Figure 9 and Figure 10 on pages 21-22). The relative size of a feature has correlation to how
much attention it draws; the larger, the more attention. Finally, the location is varied to determine any
potential importance. BN+AI has one factor at three levels, and two factors at two levels. Figure 16 show
the breakdown. Factors are in the center column (font style, size, and location), and are further broken
down in the right column. For example font style is broken down into Tall man, CAPS, and Normal. Figure
17 shows the variations in font style and size for BN+AI.

Tall man
Font Style

CAPS
Normal

Brand Name +
Active Ingredient

Medium
Size
Large
Left
Location
Right
Figure 16: Breakdown of BN+AI factors and levels

Figure 17: BN+AI font style variations. In order from top to bottom: Tall man, CAPS, Normal

Concentration and volume are similarly broken down by size and location for the same reasons as
BN+AI (refer to Figure 18). There are three different styles of displaying the concentration and volume
while still following FDA guidelines. Figure 19 shows the various styles for concentration and volume.
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Standard style indicates the current format of displaying the concentration (10,000 units/mL). Scientific
notation is often used in engineering when several orders of magnitude is needed. In this case, 10,000
units/mL, is replaced by 1E4 units/mL. This is a more compact form of displaying the number, and doesn’t
require the user to count the number of zeroes.

Standard
Style

Scientific
Notation
O'Donnel's
format

Concentration
+ Volume

Medium
Size
Large
Near BN/AI
Location

Opposite
BN/AI

Figure 18: Breakdown of concentration and volume factors and levels

Figure 19: Variations of Style for concentration and volume. In order from left to right: Standard, Scientific, O’Donnel’s

Kelsey O’Donnell is an undergraduate visual design student at Bucknell University supporting the project.
She developed an alternative way of displaying concentration and volume (see Figure 20) while following
FDA guidelines. The total concentration is divided by the total volume, and the resulting concentration
per milliliter is displayed below. This should better differentiate the total concentration from the unit
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concentration displayed on the label. The concentration and volume feature has one factor at three levels,
and two factors at two levels.

Figure 20: O’Donnell’s design for concentration and volume, and highlighted in a sample design

Delivery method has two factors that can vary: font and orientation. Figure 21 shows the way the
factors are organized. Normal and bold fonts can both draw attention, depending on the font style of the
text around it [21]. Orientation accomplishes a similar function, and the horizontal or vertical orientation
is seen on several of the existing labels (Figure 10 and Figure 11 on page 22). The location will be the same
as the storage method. Figure 22 shows the various forms of delivery method. The delivery method feature
has two factors at two levels.

Normal
Font
Bold

Delivery
Method

Horizontal
Orientation
Vertical
Figure 21: Breakdown of delivery method factors and levels
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Figure 22: Various forms of Delivery Method. Two on the left are oriented vertically.

Storage method has three factors assigned to it: size, location, and orientation. Figure 23 shows
the various factors and the respective levels. The storage method feature can vary in font and orientation
like the delivery method feature for the same reasons. The location of delivery method and storage
method are combined to reduce the total number of factors, and to maintain consistency in the sample
labels. All existing labels have these two features displayed together. Figure 24 shows the various forms
of the storage method used in the sample labels. The storage method feature has three factors at two
levels.

Small
Size
Medium

Storage
Method

Location

Near
Warnings
Opposite
Warnings
Horizontal

Orientation
Vertical
Figure 23: Breakdown of storage method factors and levels
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Figure 24: Various forms of storage method. The two features on the left are oriented vertically.

Figure 25 shows the factor for the lot and expiration feature. On existing labels, the formatting
and the size don’t change. These are stamped on after the rest of the label have been printed. To reflect
this consistency, the only factor for lot and expiration is location. This feature has one factor at two levels.

Lot +
Expiration

Left

Location
Right
Figure 25: Breakdown of lot and expiration factor and level

The warnings on the existing labels consistently span the height of the package. Figure 26 shows
the breakdown of the factor. To reflect this in the sample labels, the warning feature will be a vertical strip
located on either a side or in the center. Again, this feature has one factor at two levels.

Side

Warnings

Location
Center
Figure 26: Breakdown of the warning factor and level

In total, there are two factors at three levels (3^2) and eleven factors at two levels (2^11). Using
a partial factorial with a 100% efficiency [31], it is necessary to produce a minimum 36 unique sample
labels for the questionnaire.
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2.

Design of Samples
The next step is to determine the necessary combination of these factor levels to produce

meaningful results. The SAS macro %mktex and %mktlab is used to design the samples [32] [33]. The
following code is used to setup the design of the samples.
%𝑚𝑘𝑡𝑒𝑥(3 ∗∗ 2 2 ∗∗ 11, 𝑛 = 36);
%𝑚𝑘𝑡𝑙𝑎𝑏(𝑑𝑎𝑡𝑎 = 𝑑𝑒𝑠𝑖𝑔𝑛, 𝑖𝑛𝑡 = 𝑓1 − 𝑓3)
𝑝𝑟𝑜𝑐 𝑝𝑟𝑖𝑛𝑡; 𝑟𝑢𝑛;

(7)
(8)
(9)

The output can be found in Appendix E. A few rows have been reproduced in Table 13.
Table 13: Abridged design of samples

Obs f1 f2 f3 x1 x2 x3 x4 x5 x6 x7 x8 x9 x10 x11 x12 x13
1
2

1
1

1
1

1
1

1
1

1
1

1
1

1
1

1
2

1
2

1
2

1
1

1
2

1
2

1
1

1
2

1
2

Each of the factors have been assigned to an x* value. For example, x1 indicates the font style
used for the BN+AI features. The variable x2 indicates the style used for the concentration and volume
features. The variables f1-f3 is necessary for the program to recognize how many choices per questions
are needed. A MATLAB script (see Appendix F) was used to decode the numerical values from SAS into
literal descriptions of sample design. For example, Figure 27 and Figure 28 show the output from Obs 1
and 2 of Table 13 respectively.

Figure 27: Decoded Design (Obs) 1 from SAS. First row denotes the feature. Other rows specify the properties.

Figure 28: Decoded Design (Obs) 2 from SAS. First row denotes the feature. Other rows specify the properties.
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Using each of these decoded design descriptions, the labels were created. Every specific variation
of each feature was created at the start of the process and copied into the final design. This is to remain
consistent in the size and quality of every feature in every sample design. Figure 29 and Figure 30 show
the designs from the descriptors in Figure 27 and Figure 28 respectively. The full set of images with
accompanying descriptions used can be found in Appendix G.

Figure 29: Sample Design 1, as described by Figure 27

Figure 30: Sample Design 2, as described by Figure 28

The BN+AI parameters for both Figure 29 and Figure 30 are the same, and so the top left of both labels
appear exactly the same. Lot and expiration are located on opposite sides of the centerline because they
are specified as “Left” and “Right” in Figure 27 and Figure 28 respectively. Concentration uses the same
format in both figures, but have different locations and sizes. This is shown in the above figures: Figure 29
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has the concentration left of the center and is smaller than the one shown in Figure 30. Delivery method
and storage method for both labels are “Normal” (not bolded) and near the warning label, but they have
different orientations. Figure 29 has these features in a horizontal orientation while Figure 30 has these
features in a vertical orientation. Finally the warning label appears on the “Side” in Figure 29 versus the
“Middle” in Figure 30.

D.

Design of Survey
The pairing of the designs is done using another SAS macro: %choiceff. This macro creates the

combination of images that will best show the relations between the thirteen factors. There are a total of
36 questions, each with three images. Table 14 show the output for the first set of choices in the survey,
which requires designs (“Index”) 11, 22, and 32. The other parameters are also displayed in the table.
These numbers are necessary later on when inputting data back into SAS. Appendix 0 contains the rest of
the output. The person taking the survey then chooses which of the three they like the most.

Table 14: Output from SAS describing the 1st choice set

The sample designs are put into a web-based survey hosted by Qualtrics. The software allows for
randomized display of the choice sets, and the randomizer was enabled to prevent bias in the responses
from multiple people seeing the choice sets in the same order. The participant would select the image
most preferred from images like those shown in Figure 31. The complete survey can be found in Appendix
I. In addition to the images, a brief consent statement is included to comply with IRB regulations. Some
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demographic information is also collected in for potential future analysis. No further identifying
information is stored, and the survey software is password protected.

Figure 31: Sample choice set from Qualtrics Survey.
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E.

Results and Utility Functions
The survey was sent to pharmacists, pharmacy technicians, and nurses at Geisinger, and 53

responses were recorded and analyzed. Another SAS macro (%mktmerge) is used to combine the design
of the survey with the results. The variable des1 contains a numeric list of the design parameters and
res1 contains the results of the experiment.

%mktmerge (design=des1, data=res1, out=resmer,
nsets=36, nalts=3, setvars=choose1-choose36 )

(10)

The software then executes a regression in order to fit the results. Analysis of Variance (ANOVA) of the
regression model outputs the factors, polynomials for utility functions, and the importance of each factor
(accounting for the variance). Appendix J contains the input to SAS for this analysis. The output from SAS
is shown in Table 15.

Utility functions are polynomials generated from the utility column. If the number of utility
variables associated with the factor is n, then the degree of the polynomial is n-1. For example, the utility
function for the first factors would be:
1.14𝑡 2 − 1.46𝑡 + 0.313
The variable t ranges from 1 to the number of levels for that factor. The maximum of the function would
indicate the user preference of that factor for that feature. The top four factors in terms of importance
have been plotted in Figure 32. The other utility functions have also been maximized, and the MATLAB
script used can be found in Appendix K.

45
Table 15: Variables for Utility Functions and Importance.

Label
x1, 1
x1, 2
x1, 3
x2, 1
x2, 2
x2, 3
x3, 1
x3, 2
x4, 1
x4, 2
x5, 1
x5, 2
x6, 1
x6, 2
x7, 1
x7, 2
x8, 1
x8, 2
x9, 1
x9, 2
x10, 1
x10, 2
x11, 1
x11, 2
x12, 1
x12, 2
x13, 1
x13, 2

Utility
1.1424
-1.4555
0.3131
0.6135
0.2426
-0.8561
0.1558
-0.1558
0.6109
-0.6109
0.194
-0.194
-0.5734
0.5734
0.3427
-0.3427
-0.7739
0.7739
-0.9424
0.9424
-0.6502
0.6502
0.1283
-0.1283
0.4936
-0.4936
0.5877
-0.5877

Importance (% Utility Range)
17.35

9.815

2.08
8.161
2.591
7.659
4.578
10.337
12.588
8.685
1.714
6.593
7.85
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Utility Functions
12
x1 - BN+AI Font Style
x2 - C+V Style
x8 - Del. M Font Style
x9 - Del. M Orientation

10

8

6

4

2

0

-2
1

1.2

1.4

1.6

1.8

2
Level

2.2

2.4

2.6

2.8

3

Figure 32: Utility functions for x1, x2, x8, and x9. The maximums of these functions can be found in Table 16

The same analysis was done for each individual category of respondents (pharmacists, pharmacy
technicians, and nurses), but the end results did not vary. There was some variation in the importance
rating, but less than 0.1%, and the maximums of every utility function was the same. The maximums of
the utility functions for each factor can be found in Table 16. A label generated based on Table 16 is shown
in Figure 33.

Table 16: Maximums of every utility function

all

x1

x2

x3

x4

x5

x6

x7

x8

x9

x10

x11

x12

x13

3

3

2

2

2

1

2

1

1

1

2

2

2
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These values from Table 16 correspond to a label with (realized in Figure 33):







Brand Name and Active Ingredient:
Concentration and Volume:
Lot and Expiration:
Delivery Method:
Storage Method:
Warnings:

Normal Style, Large size, Located on the right
O’Donnell’s style, Medium size, Located opposite BN+AI
Located on the Right
Normal Style, Horizontal
Small Size, Located opposite warnings, Horizontal
Located in the Center

Figure 33: Most preferred label format

The importance of each factor is organized in Table 17. The font style of the Brand Name and
Active Ingredient is the most important factor in making a selection. The orientation and font of the
delivery method come next in terms of importance. These ratings of relative importance can be applied
to the new metric as potential weights for these features.

F.

Limits of the Conjoint Analysis
There are some limitations to the results of the conjoint analysis, most of which cannot be

addressed without further iterations of the study. The user preferences are consistent throughout each
user group, but the percent importance values differ slightly. For example, the BN+AI Font Style
accounts for about 20% of the variance, and 17% for the two other groups. There are slight variations in
each individual group, and may be related to the way the staff perceives the labels. Also, due to the
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computational limitations of the conjoint, not all features are displayed on the sample labels. These
additional labels could potentially affect the user preferences.

Table 17: Relative importance of each factor sorted from greatest to least.

FACTOR
BN+AI Font Style
Del. M. Orientation
Del. M. Font
C+V Style
Storage M. Size
BN+AI Location
Warnings Location
C+V Size
Storage M. Orientation
C+V Location
Lot/Exp. Location
BN+AI Size
Storage M. Location

Importance
17.35
12.588
10.337
9.815
8.685
8.161
7.85
7.659
6.593
4.578
2.591
2.08
1.714

The way the labels are displayed in the survey is not perfectly representative of the physical
labels as presented to the user. The labels in the pharmacies are wrapped around a cylinder, so features
on the left and right side of the sample labels actually appear adjacent if the vial is oriented in a certain
way. Additionally, only half of the label is visible at a time, without physically rotating the container.
These differences could influence the importance of the location factor for the various features
displayed. A new survey, with the labels digitally wrapped around a cylinder in various orientations will
be necessary to eliminate this potential source or error in the conjoint analysis.
The conjoint is limited to heparin labels only. The percent importance and user preferences may
differ depending on the drug type or individual drugs. Different emphasis may be placed on pill labels
versus injection labels, or there may be a difference between insulin and heparin. The concentration for
the insulin vials are all 100 units/mL, so maybe the BN+AI has greater importance for the insulin labels.
Individual labels may be necessary for each drug, but that is beyond the scope of this thesis
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V.

Failure Modes and Effects Analysis

A.

Background
In this section, Failure Modes and Effects Analysis (FMEA) is used to identify how certain features

on the labels might fail, and what the resulting effects may be. FMEA was originally developed in the 1950s
to identify problems in systems before the failure actually occurred [34]. The general premise behind
FMEA is to assemble a multi-disciplinary team familiar with the process or design and systematically
brainstorm how the design or process can break down. For this thesis, interviews with hospital staff were
conducted using the Cognitive Task Analysis (CTA) method in order to build a process flow diagram. Failure
modes were then identified and rated on severity, frequency, and detection effectiveness based on a preestablished scale. The multiplicative product of these ratings is called the risk priority number, and it is
used to rank the failures by risk or importance.
FMEA has been widely used in the automotive industry to minimize failures. Ford Motor Company
publishes a FMEA handbook [35] that outlines how the company utilizes FMEA as well as how to apply
FMEA to other systems. According to Parry, FMEA has also been utilized several times in the past at
Geisinger in order to reduce errors [4]. The current barcoding and double-check process is a result of those
analyses.

B.

Process Diagram
Three of Geisinger’s staff (two pharmacy techs and a shipping/receiving manager) were asked to

walk through the process of preparing a drug, paying specific attention to what information was
referenced at each stage. The resulting information was combined into a process diagram in Figure 35 on
the next page.
All drugs used at Geisinger are delivered to the Drug Receiving department from various
manufacturers and suppliers. As the name implies, the drugs are unpacked, checked, and sorted. The
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National Drug Code (NDC) is used to confirm delivery of the correct drugs via the delivery manifest. Lot
and expiration are also checked at this point to ensure no expired drugs enter the system. Using the NDC
and lot numbers, an internal identification number is assigned to the drugs. These drugs are then sorted
based on the destination pharmacy and then delivered to the respective stock rooms. The NDC, lot
number, and internal ID number contain information about the drug name, concentration, volume, etc.,
but are not used directly by the staff at this stage.
Next, either a pharmacy technician or pharmacist receives a drug order from elsewhere in the
hospital, detailing the patient, drug name, concentration, volume, delivery method, and special
instructions where applicable. The drug name, concentration, volume, and delivery method is then used
to select the correct drug from the stock room shelf. Once the correct drug has been selected, it is
prepared appropriately. If the drug is a liquid, it is mixed into an IV bag or syringe, and a new internal label
is applied. Solid drugs are repackaged in plastic and paper like the one shown in Figure 34.
.

Figure 34: Pill repackaged in Geisinger’s pharmacy
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Figure 35: Process Diagram for drug delivery

52
During the repackaging process, the manufacturer barcode is scanned to ensure the proper drug
is selected. The repackaged drug is given a new internal barcode that contains patient and drug
information. Pharmacy technicians are required to have the prepared drug verified by a pharmacist, and
pharmacists are required to have another pharmacist check the prepared drug. The drugs repackaged by
pharmacists and pharmacy techs no longer use the manufacturer label. The drugs are then sent to the
appropriate patient. After verifying the drug again using either the Geisinger label information or barcode,
it is administered by the physician or nurse.
Some commonly used drugs are delivered from the main pharmacy stock room to stock rooms on
the patient floor. These drugs have very low concentrations (unlikely to cause issues), and are not
controlled (no narcotics). These common drugs stay in the manufacture package, and are not assigned
Geisinger’s internal label. Nurses and physicians on the patient floors can use these “floor stocks” to
administer drugs to patients without waiting for the drug to be delivered from the pharmacy. Drug name,
concentration, volume, delivery method, expiration, and barcode (in some wards) are checked by the
nurse or physician administering the drug. Another nurse or physician is required to verify the information
before giving the drug to the patient.

C.

FMEA Table
Using the process diagram above, a FMEA table is made based on the label features used in the

diagram (Figure 35). Table 18, Table 19, Table 20, Table 21, Table 22, Table 23, and Table 24 are broken
down by the label features. The next column (potential failure) is then organized by the person along the
process that might make an error, such as a pharmacist misreading the drug name. The potential effects
of the failure is stated and rated in the next two columns, with the severity rating based on the scale
shown in Figure 36. The potential cause of the error is listed in the next column. Frequency is then rated
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based on the scale shown in Figure 37. Detection methods for these errors are described in the next
column for each error, and the effectiveness of the detection is based on the scale shown in Figure 38.
The Risk Priority Number (RPN) is the product of the severity, frequency, and detection ratings.
Recommended actions are listed in the final column.

Figure 36: Severity Scale used by Geisinger’s Joint Commission FMEA

Figure 37: Frequency or Occurrence Scale used for Geisinger’s joint commission FMEA
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Figure 38: Detection effectiveness scale used for Geisinger’s joint commission FMEA.

1.

Drug Name (Table 18)
The potential failure mode for drug name comes from misreading the label. For pharmacists and

pharmacy technicians, the effects of misreading the drug name is preparing the wrong drug and sending
it out to patients. For nurses, misreading the drug name means administering the wrong drug to the
patient. These failures have very high severity ratings due to the potential impact on the patient. The
rating is lower for pharmacy technicians and pharmacists because they are not directly administering the
drug to the patient. In addition, the severity rating is slightly lower for the pharmacy technician because
they typically handle (and have access to) less dangerous drugs. Frequency for this type of error is low,
and is almost always caught using the barcode verification. Nurses misreading the drug name has the
highest risk priority number due to a low detection effectiveness. It is difficult to figure out exactly what
the patient was mistakenly administered after injection or ingestion.
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Drug Name

Prepare
Misread (Pharm) wrong drug

Drug Name

Prepare
Misread (Ptech) wrong drug

Drug Name

Administer
Misread (Nurse) wrong drug

2.

Label misread,
leading to
selection of
8 wrong drug
Label misread,
leading to
selection of
7 wrong drug
Label misread,
leading to
selection of
9 wrong drug

Current
Design or
Process
Controls

Electronic
Database
Verified +
1 Double Check
Electronic
Database
Verified +
1 Double Check
Electronic
Database
Verified +
1 Double Check

Risk Priority #
(SxFxD)

Causes
and/or
Failure
Mechanisms

Detection
Effectiveness
(D: 1=certain,

Potential
Potential
Failure Mode Effects of
(person)
Failure

Frequency Rating
(F: 1=1/1.5M,
10=1/2)

Label
Features

Severity
(S: 1=none,
10=hazardous)

Table 18: FMEA Table for Drug Name (part 1 of 7)

Recommended
Action(s)

2

Wider
implementation of
16 electronic database

2

Wider
implementation of
14 electronic database

5

Wider
implementation of
45 electronic database

Concentration (Table 19)
Potential failure modes for the concentration are similar to that of the drug name. Misreading the

number or units will lead to putting the improper amount of the drug into the hospital’s packaging. The
severity of improper concentration is approximately the same as giving the wrong drug, especially if the
patient receives the drug in too high of a concentration. Severity ratings for giving the patient lower
concentration are lower due to less severe consequences. Under-dosing a patient isn’t as dangerous as
over-dosing. The frequency of misreading the concentration is higher than the other errors, especially
with nurses. According to Dr. Parry, the most commonly reported error is a nurse making a mistake in
concentration. Also, pharmacy technicians are slightly more likely to mistake the concentration than
pharmacists. Detection rate of errors in concentration is the same as detection rate of errors in drug name.
These errors are prevented by the electronic barcode system where applicable, and by the double check
method: one other person must verify the concentration before administering or sending it out of the
pharmacy. The RPN for a nurse misreading the concentration is very high due to the uncertainty in
detection, the relatively high frequency, and the potentially adverse effect on the patient.
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Concentration

Use too
much in bag
Misread (Pharm) or syringe

Concentration

Use too little
in bag or
Misread (Pharm) syringe

Concentration

Use too
much in bag
Misread (Ptech) or syringe

Concentration

Use too little
in bag or
Misread (Ptech) syringe

Concentration

Inject too
much into
Misread (Nurse) patient

Concentration

Inject too
little into
Misread (Nurse) patient

3.

8

6

8

6

9

6

Label misread,
leading to
selection of
wrong drug
Label misread,
leading to
selection of
wrong drug
Label misread,
leading to
selection of
wrong drug
Label misread,
leading to
selection of
wrong drug
Label misread,
leading to
selection of
wrong drug
Label misread,
leading to
selection of
wrong drug

2

1

3

1

3

1

Current
Design or
Process
Controls

Electronic
Database
Verified +
Double Check
Electronic
Database
Verified +
Double Check
Electronic
Database
Verified +
Double Check
Electronic
Database
Verified +
Double Check
Electronic
Database
Verified +
Double Check
Electronic
Database
Verified +
Double Check

Risk Priority # (SxFxD)

Causes
and/or
Failure
Mechanisms

Detection Effectiveness
(D: 1=certain, 10=none)

Potential
Potential
Failure Mode Effects of
(person)
Failure

Frequency Rating
(F: 1=1/1.5M, 10=1/2)

Label
Features

Severity
(S: 1=none,
10=hazardous)

Table 19: FMEA Table for Concentration of the drug (part 2 of 7)

Recommended
Action(s)

2

Wider
implementation of
32 electronic database

2

Wider
implementation of
12 electronic database

2

Wider
implementation of
48 electronic database

2

Wider
implementation of
12 electronic database

5

Wider
implementation of
135 electronic database

5

Wider
implementation of
30 electronic database

Volume (Table 20)
Errors in volume are very similar to errors with concentration. The cause and effects misreading

the volume are too much or too little of the drug being delivered to the patient. The severity is
approximately the same as the concentration, as mistaking the volume can just as easily result in the
delivery the improper amount. The frequency of this error is less than that of the concentration because
there is usually another visual cue for the volume of the container (size/weight of the manufacturer’s
container). As with concentration, double checking the volume with another person is a good way of
preventing errors. The electronic verification (when available) of scanning the barcode is also an effective
way of preventing the error. Though not quite as high as errors in concentration, nurses making a mistake
in volume still results in a high RPN.
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Volume

Use too
much in bag
Misread (Pharm) or syringe

Volume

Use too little
in bag or
Misread (Pharm) syringe

Volume

Use too
much in bag
Misread (Ptech) or syringe

Volume

Use too little
in bag or
Misread (Ptech) syringe

Volume

Inject too
much into
Misread (Nurse) patient

Volume

Inject too
little into
Misread (Nurse) patient

4.

8

6

8

6

9

6

Label misread,
leading to
selection of
wrong drug
Label misread,
leading to
selection of
wrong drug
Label misread,
leading to
selection of
wrong drug
Label misread,
leading to
selection of
wrong drug
Label misread,
leading to
selection of
wrong drug
Label misread,
leading to
selection of
wrong drug

1

1

1

1

1

1

Current
Design or
Process
Controls

Electronic
Database
Verified +
Double Check
Electronic
Database
Verified +
Double Check
Electronic
Database
Verified +
Double Check
Electronic
Database
Verified +
Double Check
Electronic
Database
Verified +
Double Check
Electronic
Database
Verified +
Double Check

Risk Priority # (SxFxD)

Causes
and/or
Failure
Mechanisms

Detection Effectiveness
(D: 1=certain, 10=none)

Potential
Potential
Failure Mode Effects of
(person)
Failure

Frequency Rating
(F: 1=1/1.5M, 10=1/2)

Label
Features

Severity
(S: 1=none,
10=hazardous)

Table 20: FMEA Table for Volume of the drug (part 3 of 7)

Recommended
Action(s)

2

Wider
implementation of
16 electronic database

2

Wider
implementation of
12 electronic database

2

Wider
implementation of
16 electronic database

2

Wider
implementation of
12 electronic database

5

Wider
implementation of
45 electronic database

5

Wider
implementation of
30 electronic database

Expiration (Table 21)
Errors with expiration are slightly different than the errors discussed so far. An expired drug may

not have any adverse effects on the patient, especially if it was recently expired. The severity rating is
therefore lower than administering too much or using the wrong drug. However, detection of this error is
unlikely, especially if the double check fails. A nurse administering expired drug is essentially undetectable
unless an adverse drug event occurs immediately. Another possibility of misreading the expiration is
mistakenly throwing it away. In this case, the severity is non-existent for the patient. As with other errors,
overall frequency is too low for accurate statistics at one hospital. The detection efficiency not very good,
especially if the double checking fails. However, throwing the drug away before it is expired is impossible
to detect, unless someone sorts and inventories the trash.
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Use expired
drug in bag
Misread (Pharm) or syringe

Current
Design or
Process
Controls

Label misread
6 or obscured.

Double
1 checked

Throw away
Misread (Pharm) useful drug
Use expired
drug in bag
Misread (Ptech) or syringe

Label misread
2 or obscured.

1 N/A

Label misread
6 or obscured.

Double
1 checked

Label misread
2 or obscured.

1 N/A

Expiration

Throw away
Misread (Ptech) useful drug
Use expired
drug in bag
Misread (Nurse) or syringe

Label misread
6 or obscured.

Double
1 checked

Expiration

Throw away
Misread (Nurse) useful drug

Label misread
2 or obscured.

1 N/A

Expiration

Expiration

Expiration

Expiration

5.

5

10

2

10

8

10

Risk Priority # (SxFxD)

Causes
and/or
Failure
Mechanisms

Detection Effectiveness
(D: 1=certain, 10=none)

Potential
Potential
Failure Mode Effects of
(person)
Failure

Frequency Rating
(F: 1=1/1.5M, 10=1/2)

Label
Features

Severity
(S: 1=none,
10=hazardous)

Table 21: FMEA Table for Expiration of the drug (part 4 of 7)

Recommended
Action(s)

30 no further action

20

12 no further action

20

48 no further action

20

Storage (Table 22)
The storage method is used to describe what kind of conditions to store the drug (some

refrigeration required for example). Misreading the storage instructions would lead to improperly storing
the drugs, potentially leading to the deterioration of the drug. This poses some danger to the patient,
similar to using expired dugs. Frequency, again is low, especially because the hospital already has
protocols for storing drugs. Detection is rated as a 3, as it is very likely to be caught with occasional
inventory.
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Storage

Misinterpret
(Pharm)

Storage

Misinterpret
(Ptech)

Storage

Misinterpret
(Nurse)

Improper
storage,
waste drugs
Improper
storage,
waste drugs
Improper
storage,
waste drugs

Current
Design or
Process
Controls

Risk Priority # (SxFxD)

Causes
and/or
Failure
Mechanisms

Detection Effectiveness
(D: 1=certain, 10=none)

Potential
Potential
Failure Mode Effects of
(person)
Failure

Frequency Rating
(F: 1=1/1.5M, 10=1/2)

Label
Features

Severity
(S: 1=none,
10=hazardous)

Table 22: FMEA Table for Storage of the drug (part 5/7)

Recommended
Action(s)

label misread or
6 obscured.

Occational
1 inventory

3

18 N/A

label misread or
6 obscured.

Occational
1 inventory

3

18 N/A

label misread or
6 obscured.

Occational
1 inventory

3

18 N/A

Incorrect
Delivery Method Misread (Pharm) internal label

label misread or
7 obscured.

Incorrect
Delivery Method Misread (Ptech) internal label

label misread or
7 obscured.

Deliver drug
Delivery Method Misread (Nurse) incorrectly

label misread or
9 obscured.

Current
Design or
Process
Controls

Electronic
Database
Verified +
1 Double Check
Electronic
Database
Verified +
1 Double Check
Electronic
Database
Verified +
1 Double Check

Risk Priority # (SxFxD)

Causes
and/or
Failure
Mechanisms

Detection Effectiveness
(D: 1=certain, 10=none)

Potential
Potential
Failure Mode Effects of
(person)
Failure

Frequency Rating
(F: 1=1/1.5M, 10=1/2)

Label
Features

Severity
(S: 1=none,
10=hazardous)

Table 23: FMEA Table for Delivery Method of the drug (part 6 of 7)

Recommended
Action(s)

2

Wider
implementation of
14 electronic database

2

Wider
implementation of
14 electronic database

5

Wider
implementation of
45 electronic database
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6.

Delivery Method (Table 23)
Errors in misreading the delivery method are very severe. Delivering a drug meant to be mixed in

an IV bag directly into a patient is what caused the heparin incident discussed in the introduction. If the
pharmacist or pharmacy tech makes an error reading the delivery method, the wrong hospital label will
be passed on, and potentially harm the patient. A nurse making this error is more severe because it
directly impacts the patient with no intermediate steps or potential of catching the error. Frequency is
low due to the system in place at Geisinger. Detection is high for pharmacists and pharmacy technicians,
but much lower for nurses. Often times, the error is caught after the drug is administered to the patient.

7.

Barcode (Table 24)
The barcode is used to verify the contents before preparing a drug, and in some places,

administering a drug. A scanner is needed to interpret the barcode, and an error results if the scanner is
unable to read it. This error happens often compared to other errors discussed above, usually due to small
vial sizes. The curvature on small bottles sometimes makes the barcode fail. In relation to the patient, this
failure is relative harmless, causing more inconvenience for the nurse or physician. Orienting the barcodes
such that the curvature doesn’t affect the scanner could potentially solve issue.
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Barcode

Unable to Scan
(Pharm)

Manually
Input info

Barcode

Unable to Scan
(PTech)

Manually
Input info

Barcode

Unable to Scan
(Nurse)

Nurse
performs
override

D.

Barcode
obstructed or
curvature
makes
scanning
4 impossible
Barcode
obstructed or
curvature
makes
scanning
4 impossible
Barcode
obstructed or
curvature
makes
scanning
4 impossible

Current
Design or
Process
Controls

Risk Priority # (SxFxD)

Causes
and/or
Failure
Mechanisms

Detection Effectiveness
(D: 1=certain, 10=none)

Potential
Potential
Failure Mode Effects of
(person)
Failure

Frequency Rating
(F: 1=1/1.5M, 10=1/2)

Label
Features

Severity
(S: 1=none,
10=hazardous)

Table 24: FMEA Table for Barcode (part 7 of 7)

Recommended
Action(s)

5 N/A

1

Barcodes oriented
20 axially with vial

5 N/A

1

Barcodes oriented
20 axially with vial

5 N/A

1

Barcodes oriented
20 axially with vial

High RPN
Based on the RPN, the errors listed in Table 25 are the most problematic. Nurses misreading

anything on the label generally results in a high RPN due to the combination of poor detection
effectiveness (often too late), higher relative frequency, and high severity. Concentration, drug name,
volume, expiration, and delivery method require special attention on the labels as they have the highest
RPN. There is no major discrepancy between the results of the FMEA RPN and the results of the conjoint
analysis as both highlight similar important features. Other features have lower frequency or better
detection leading to lower RPN. More widespread implementation of the electronic scanning system is
the most effective way to prevent these potential errors, as people can always misread text on a label.
Storage and barcode do not have high RPNs. The RPN for barcodes is 20, due to a very high detection rate,
and low impact on the patient. An error obviously occurs if the scanner is unable to read the barcode. The
RPN for storage method is 18, due to a very low frequency rating, and moderate impact on the patient.
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Concentration

Inject too
much into
Misread (Nurse) patient

Expiration

Use too
much in bag
Misread (Ptech) or syringe
Use expired
drug in bag
Misread (Nurse) or syringe

Drug Name

Administer
Misread (Nurse) wrong drug

Volume

Inject too
much into
Misread (Nurse) patient

Concentration

Deliver drug
Delivery Method Misread (Nurse) incorrectly

Current
Design or
Process
Controls

Label misread,
leading to
selection of
9 wrong drug
Label misread,
leading to
selection of
8 wrong drug

Electronic
Database
Verified +
3 Double Check
Electronic
Database
Verified +
3 Double Check

Label misread
6 or obscured.
Label misread,
leading to
selection of
9 wrong drug
Label misread,
leading to
selection of
9 wrong drug

Double
1 checked
Electronic
Database
Verified +
1 Double Check
Electronic
Database
Verified +
1 Double Check
Electronic
Database
Verified +
1 Double Check

label misread or
9 obscured.

Risk Priority # (SxFxD)

Causes
and/or
Failure
Mechanisms

Detection Effectiveness
(D: 1=certain, 10=none)

Potential
Potential
Failure Mode Effects of
(person)
Failure

Frequency Rating
(F: 1=1/1.5M, 10=1/2)

Label
Features

Severity
(S: 1=none,
10=hazardous)

Table 25: FMEA table for failure modes with RPN > 45

Recommended
Action(s)

5

Wider
implementation of
135 electronic database

2

Wider
implementation of
48 electronic database

8

48 no further action

5

Wider
implementation of
45 electronic database

5

Wider
implementation of
45 electronic database

5

Wider
implementation of
45 electronic database
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VI.

Modified Aggregate Feature Commonality Index

A.

Methodology
The Modified Aggregate Feature Commonality Index (MAFCI) was created based on the results of

the conjoint analysis and the FMEA. The importance (% utility range) of the various features are used as
weights in the AFCI analysis. Individual feature commonality index calculations are kept the same as the
FCI analysis (see section III.A for details). The methodology of the FCI analysis is concise and able to
highlight differences (or lack thereof) in feature size and location.
The means of the importance value for each feature in Table 17 are used as weights for the
aggregate commonality. The means for the features are shown in Table 26. The results of the averages
reflect weights likely used in a decision matrix or Pugh’s method [26], and there are significant differences
(factor of 3) between the most and least important weights. All other features not included in the conjoint
analysis are given the same weight as the lot and expiration. The low weight of the other features reduces
the impact of variation in non-essential features. The relative importance of each essential feature is
preserved when using a weighted mean for the aggregate. The formula for the MAFACI and MAFLCI are
found in Error! Reference source not found. and Error! Reference source not found. respectively. Some
essential features do not appear on insulin and tramadol labels. In these cases, the weights and FCI are
omitted from the analysis.

Table 26: Average Feature Importance and Weights

Feature
Active Ingredient
Brand Name
Concentration
Delivery Method
Storage Method
Warnings
Lot/Expiration
Volume
Other Features

Weight
9
9
7
8
6
8
3
7
3
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𝑀𝐴𝐹𝐴𝐶𝐼 =
𝑀𝐴𝐹𝐿𝐶𝐼 =

B.

Results

1.

Heparin

∑(𝐹𝐴𝐶𝐼𝑒𝑠𝑠𝑒𝑛𝑡𝑖𝑎𝑙 ∗𝑊𝑒𝑖𝑔ℎ𝑡𝑟𝑒𝑠𝑝𝑒𝑐𝑡𝑖𝑣𝑒 )+𝐴𝐹𝐴𝐶𝐼𝑛𝑜𝑛−𝑒𝑠𝑠𝑒𝑛𝑡𝑖𝑎𝑙 ∗3
∑(𝑊𝑒𝑖𝑔ℎ𝑡𝑠)+3
∑(𝐹𝐿𝐶𝐼𝑒𝑠𝑠𝑒𝑛𝑡𝑖𝑎𝑙 ∗𝑊𝑒𝑖𝑔ℎ𝑡𝑟𝑒𝑠𝑝𝑒𝑐𝑡𝑖𝑣𝑒 )+𝐴𝐹𝐿𝐶𝐼𝑛𝑜𝑛−𝑒𝑠𝑠𝑒𝑛𝑡𝑖𝑎𝑙 ∗3
∑(𝑊𝑒𝑖𝑔ℎ𝑡𝑠)+3

(11)
(12)

Table 27 shows the results of the MAFACI and MAFLCI analysis versus the original AFACI and AFLCI.
Values that vary more than 0.02 between measures are colored blue in the table. The MAFLCI values are
almost identical to the AFLCI values, indicating that the essential features vary just as much as all features.
A higher MAFLCI versus AFLCI indicates greater consistency in the locations of the essential features. The
non-essential features would be lowering the AFLCI while not necessarily affecting the ease and accuracy
of reading the label: location of the manufacturer logo might shift around but doesn’t affect a person
looking for drug name and dosage.

Table 27: MAFCI values compared to AFCI values. Blue values indicate a >0.02 difference in the indexes

ALL
SAGENT
APP
Medefil
Vials
Pre-mandate
Post-mandate

MAFACI AFACI MAFLCI AFLCI
0.68
0.58
0.61
0.61
0.74
0.64
0.77
0.79
0.84
0.78
0.92
0.91
0.96
0.93
0.97
0.95
0.58
0.62
0.64
0.65
0.60
0.60
0.61
0.57
0.54
0.63
0.65
0.63

There is more variation between the MAFACI and the AFACI. Sagent, APP, and Medefil all had higher
MAFACI values compared to AFACI values. The non-essential features had greater variation than the
essential features. This trend is seen when some of the essential FACI values are calculated and
compared to the AFACI values separated by manufacturer Table 2, Table 3, and Table 4). Values of
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MAFACI are lower than that of AFACI for vials due to the low concentration and volume FACI (Table 5)
because these features now have more impact on the modified aggregate. The lower post-mandate
MAFACI value versus AFACI value show that there is now more variation in the essential features. Rather
than improving consistency, the new mandate has led to more variation in features that medical
professionals constantly refer to. This could lead to more errors as the features most looked at are not
as consistent.

2.

Insulin
Table 28 shows results of the MAFACI and MAFLCI analysis on the insulin labels. Only the

manufacturer Lilly is analyzed separately due to a small sample size of available labels from other
manufacturers. The modified and original aggregate location commonality indexes for the manufacturer
Lilly are the same, indicating that the locations of the all the features vary by the same amount. The
essential features do not get any special consideration in Lilly’s layout. The change in the MAFLCI from the
AFLCI of all insulin labels indicates that the location of the essential features is actually more consistent
than all heparin labels.
In terms of relative comparisons with heparin, the MAFCI for Lily labels are actually similar to
those of Sagent (0.76 to 0.74 respectively), one of the less consistent labels in the heparin family. Also,
the overall MAFCI value is now the same as heparin, while before the AFACI showed that insulin was more
consistent. The non-essential features increased the commonality index while not necessarily maintaining
consistency of features like brand name (FACI = 0.58. See Table 8).
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Table 28: MAFACI and MAFLCI compared to AFCI values. Blue values indicate a >0.02 difference in the indexes

ALL
Lilly

3.

MAFACI AFACI
MAFLCI AFLCI
0.76
0.59
0.68
0.63
0.81
0.76
0.76
0.76

Tramadol
Table 29 show the results of the modified analysis of tramadol packages. There isn’t any significant

difference between the indexes. The tramadol labels consisted mainly of essential features, so the AFCI
was not skewed either way by the FCI of non-essential features. The differences come from the differing
weights assigned to the various features. The tramadol labels are the most consistent when viewed as a
drug set. However, when ranking MAFACI by manufacturers in the study, Mylan is less consistent than the
heparin manufacturer APP but better than the insulin manufacturer Lilly.

Table 29: MAFCI and MAFLCI compared to AFCI values.

ALL

C.

MAFACI AFACI
MAFLCI AFLCI
0.80
0.78
0.88
0.86

Ramifications
This new metric could give a better correlation between label commonality and error rates, as the

commonly used features are given more weight. In addition, a comparison between the modified
aggregate and the original measure would be helpful in suggesting improvements to product family labels.
By assigning significant weights to the essential features, differences between MAFCI and AFCI can be
generalized to show areas in need of improvement. If the MAFCI is lower than the AFCI, the essential
features will need better cohesion across the labels, while less attention can be paid to the non-essential
features. If the MAFCI is much greater than the AFCI, to a point where the value is acceptable, then it is
possible that no revision is necessary. The identification of the essential features, as well as their relative
importance, can be further applied in the development of future metrics and studies.
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The new method of computing the aggregate also allows for more flexibility for individual drugs.
A new set of weights can be computed to reflect the different usage for various drugs. The MAFCI is
currently based on heparin labels, but can be adapted for use with other labels. Another conjoint analysis
is necessary to customize the weights specifically for insulin or tramadol labels. Combined with Miller and
Cho’s experiment [25], the MAFCI should show greater correlation with the selection times than the AFCI.
There are some limitations with the MAFCI, however. The survey was only given to staff at
Geisinger, who represent a small percentage of users nationwide. The scope of the thesis is very focused
on Geisinger, but the habits at different medical institutions could lead to different results. The
methodology outlined in the Conjoint Analysis, FMEA, and Modified Aggregate sections should be applied
to several other institutions. If the resulting weights are similar, a standardized weighing system could be
applied for all hospitals. If the results from the institutions show a major difference, the weights would
need to be individualized to each institution. The MAFCI could then help individual hospitals select drugs
from various manufactures to maximize commonality.

68

VII. Conclusion and Future Work
This thesis has presented the development of a Modified Aggregate Feature Commonality Index
(MAFCI) for analyzing information on medical labels, building on the work of Shooter and Cohen [1]. Some
shortcomings of the original Aggregate Feature Commonality Index (AFCI) were addressed in the modified
index. The equal weights of all features when calculating the AFACI were replaced by more emphasis on
the essential features for the modified index. The MAFCI was the result of a conjoint analysis and FMEA
with abundant input from medical professionals at the Geisinger Medical Center in Danville. The MAFCI
and AFCI were applied to manufacturer labels commonly used at Geisinger, and the differences between
the measures were highlighted.
Correlating error statistics with the commonality indexes is difficult due to the low instances of
errors for each drug. Combined, the errors present a major problem, but the multitude of drugs available
makes individual drug error statistics difficult to properly analyze. Another issue with the commonality
indexes is the inability to analyze each label individually. It would be possible for a terribly designed label
to be consistent across multiple drugs to achieve a high commonality index.
Conjoint analysis and FMEA are useful tools for figuring out the important and commonly
features, as well as user preferences for feature design. Each analysis should focus on one aspect of the
label such as location or area. The inclusion of various styles in the conjoint analysis complicated the study
quite a bit. In addition, future incorporation of psychology measures with the conjoint analysis and FMEA
would lead to a more comprehensive tool for label designers.
The analysis done can be expanded to cover more drug labels or complete case studies of various
manufacturers. A more directed conjoint analysis can provide further insight into the interaction between
area and location for user preferences. More factors in the analysis can require the eventual survey to be
broken up into multiple pieces, or focus specifically on one or two features. Work done in parallel by the
Psychology department at Bucknell University with eye tracking can also be merged with results to further
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validate the conjoint analysis. Perception and general design theory could also be used to develop a metric
that analyses each label individually for design errors, rather than looking at the consistency across
multiple labels.

A.

Analysis of Other Drug Labels
Heparin, insulin, and tramadol are not the only sources of errors in medical administration, and

there are more labels from the manufacturers not being used at Geisinger. A commonality analysis of all
of a manufacturer’s labels could potentially help hospitals select labels that are more common in the
essential features using the MAFCI. In some cases, availability of different does is an issue and the drugs
must be purchased from different manufacturers. Even in this case, it should be possible to create a macro
or tool that helps with the selection for commonality.

Figure 39: All APP heparin vials, from company website

The features area and locations can be collected in a database for all labels from all manufactures,
and the MAFCI can be calculated by selecting the ones that are available. For example, if a hospital prefers
APP (Figure 39) as the source for heparin, but a specific dose is not available, it would be possible to
recalculate the MAFCI for each new source. The one with the highest MAFCI would have the most similar
format, especially concerning the often used features. A mockup of the program outputs can be found in
Figure 40.

70

Figure 40: Mockup of program outputs for selecting new output. Values are random and not indicative of actual MAFCI

Other drugs could be included in such a tool to help hospitals select manufacturers for the other
drugs. Some slight revision of the weights may be necessary, as the drugs analyzed in this thesis are liquid,
injection based. The essential features may be more or less important for pills as compared to liquids.
Another conjoint analysis might be necessary, but this time targeting a different delivery method.

B.

More targeted Conjoint Analysis
The conjoint analysis used in the analysis of heparin labels does not correlate directly with location

and area measures. Style and orientation were also considered in an attempt to produce a new
recommendation. A new conjoint analysis and survey could be done in order to verify the weights, and
the analysis may produce different weights for location and area. Two levels for area should be sufficient
(large and small). For location, another two levels should be sufficient. Any more levels for location would
lead to conflicts with placing features. Such conflicts happened when generating the labels for the original
conjoint analysis. Some non-essential features like NDC had to be shifted around to accommodate locating
two large features on the same side. With 8 essential features, each with two factors (Figure 41) a 100%
efficient design can be made with a minimum of 20 samples. This is verified using:
%𝑚𝑘𝑡𝑟𝑢𝑛𝑠(2 ∗∗ 16)

(13)
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The process outlined in the conjoint analysis would be repeated with the new designs to confirm the
weights for the features. New weights may be assigned for location and area measures because the
conjoint is designed such that the location and area are separated.

Size
Essential
Feature (x8)

Location

Small
Large
Left
Right

Figure 41: Factor Breakdown for essential features in new conjoint analysis

Other analyses can be done using the same method for different drugs to confirm or refute the
measures created for heparin. Different weights may result if the drug is delivered or stored differently.
Solid pills may not have the same weights as a liquid vial, while other drugs may have higher weights if
they need to be specially stored or controlled.

C.

Eye Tracking, Contrast, and other measures
Professor A. Mitchel of the psychology department at Bucknell University has also started a

preliminary perception study on the effects of location and area. An eye tracker is used to identify which
features are looked at first, as well as how long they are looked at. Initial analysis of the data has shown
that the size of the feature is the primary factor in how quickly participants focused on the feature. This
time is referred to as “time to first fixation” and can be a useful in creating a metric that describes an
individual label rather than a set.
Kelsey O'Donnell, a management student with a focus on visual design, found an FDA draft for
recommendations on label design. Key measures from the draft are a contrast ratio between background
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color and text, and color schemes for labels. A WCAG contrast ratio of less than 4.5 indicates that the text
is not sufficiently contrasted from the background [36]. Also, unrelated information should not have the
same color as information associated with it. The “1,000 USP units per mL” and warning label (boxed in
red and black) should not be the same color (Figure 42). Also, the color should not indicate the
concentration or drug name, but be used to differentiate information on the label [37].

Figure 42: Sagent Label, the incorrect coloring scheme is highlighted by back and red rectangles

The eye tracking, contrast ratio, and coloring scheme could be combined with the weighing from
the conjoint analysis to develop a metric describing individual labels. This metric would prevent
unreadable or non-optimized layouts from being selected based on a high AFCI or MAFCI. The
commonality indexes are not capable of rating how well individual labels are designed, but rather how
cohesive the labels are as a group.
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IX.

Appendix

A.

Compilation of Scanned Images Organized by Manufacturer (not to scale)

1.

Heparin – Sagent Labels
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2.

Heparin – APP
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3.

Heparin – Pfizer
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4.

Heparin – Medefil
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5.

Insulin – Lilly
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6.

Insulin – Sanofi-Aventis

7.

Insulin – Novo Nordisk
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8.

Tramadol – Mylan
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B.

AFACI MATLAB

function [ faci,b ] = AFACI(a)
%FCI Input array of values for Feature Area Commonality Index
%
'a' contains all data, with 0 indicating absence of feature
[f,d]=size(a); % f is number of features, d is number of drugs
b=[];
% b is the proportional difference
for i = 1:f
% calculating each feature, putting into b
aa=a(i,:);
a0=aa~=0;
n=sum(aa~=0);
%number of occurances
avg=sum(aa)/n; %average of values in row
bb=[];
for ii= 1:d
bb(ii)=abs(avg-aa(ii))/((avg+aa(ii))/2)*a0(ii); %calculating one
component of proportional diff
end
b(i)=sum(bb)/n;
b(isnan(b)) = 0;
end
b=b';
faci=1-sum(b)/sum(b~=0);
end
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C.

AFLCI MATLAB

function [ flci, dj ] = AFLCI( xy )
%FLCI Computes the FLCI of data, alternating columns of x and y

[r,c]=size(xy);
for i=1:c/2
x(:,i)=xy(:,(i*2)-1);
y(:,i)=xy(:,i*2);
end

ybar=[sum(y')]'./[sum(y'~=0)]';
ybar(isnan(ybar)) = 0;
xbar=[sum(x')]'./[sum(x'~=0)]';
xbar(isnan(xbar)) = 0;
dj=[];
for i = 1:r
% calculating each feature, putting into b
x1=x(i,:);
x0=x1~=0;
n=sum(x1~=0);
%number of occurances
bb=[];
for ii= 1:c/2
bb(ii)=(((xbar(i)-x(i,ii))^2+(ybar(i)-y(i,ii))^2)^0.5)*x0(ii);
%calculating one component of proportional diff
end
b(i)=sum(bb)/n;
b(isnan(b)) = 0;
end
dj=b';
flci=1-2*sum(dj)/sum(dj~=0);
end

87

D.

Preliminary Survey
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E.

Design of samples

Obs f1 f2 f3 x1 x2 x3 x4 x5 x6 x7 x8 x9 x10 x11 x12 x13
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
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29
30
31
32
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36
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F.

MATLAB SAS decoder

clear
clc
load DoE.mat
i=input('Which Design? ');
R=A(i,:);
%% Sets the parameters for the Brand Name / Active Ingredient
Design={};
Design{1,1}='Brand / Ingredient';
if R(1)==1
Design{2,1}='Tallman';
elseif R(1)==2
Design{2,1}='CAPS';
elseif R(1)==3
Design{2,1}='Normal';
end
if R(3)==1
Design{3,1}='Medium';
else
Design{3,1}='Large';
end
if R(4)==1
Design{5,1}='Left';
else
Design{5,1}='Right';
end
%% Sets the parameters for the Lot number and Expiration
Design{1,2}='Lot/Exp';
if R(5)==1
Design{2,2}='Left';
else
Design{2,2}='Right';
end
%% Sets the parameters for the Concentration and Volume
Design{1,3}='Con/Volume';
if R(6)==1
Design{2,3}='Medium';
else
Design{2,3}='Large';
end
if R(7)==1
Design{3,3}='Near AI/BN';
else
Design{3,3}='Opposite AI/BN';
end
if R(2)==1
Design{4,3}='Standard';
elseif R(2)==2

91
Design{4,3}='Scientific Notation';
elseif R(2)==3
Design{4,3}='Kelsey"s Layout';
end
%% Sets the parameters for Delivery Method
Design{1,4}='Delivery Method';
if R(8)==1
Design{2,4}='Normal';
else
Design{2,4}='Bold';
end
if R(9)==1
Design{3,4}='Horizontal';
else
Design{3,4}='Vertical';
end
%% Sets the parameters for Storage Method
Design{1,5}='Storage Method';
if R(10)==1
Design{2,5}='Small';
else
Design{2,5}='Medium';
end
if R(11)==1
Design{3,5}='Near Warnings';
else
Design{3,5}='Opposite Warnings';
end
if R(12)==1
Design{4,5}='Horizontal';
else
Design{4,5}='Vertical';
end
%% Sets the parameters for the Warning labels
Design{1,6}='Warnings';
if R(13)==1
Design{2,6}='Side';
else
Design{2,6}='Middle';
end
%% Compiles and displays the design
Design
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G.

All Sample Labels with accompanying descriptions

Sample Design 1

Sample Design 2
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Sample Design 3

Sample Design 4
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Sample Design 5

Sample Design 6
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Sample Design 7

Sample Design 8
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Sample Design 9

Sample Design 10

97

Sample Design 11

Sample Design 12
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Sample Design 13

Sample Design 14
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Sample Design 15

Sample Design 16
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Sample Design 17

Sample Design 18
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Sample Design 19

Sample Design 20
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Sample Design 21

Sample Design 22
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Sample Design 23

Sample Design 24
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Sample Design 25

Sample Design 26
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Sample Design 27

Sample Design 28
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Sample Design 29

Sample Design 30
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Sample Design 31

Sample Design 32

108

Sample Design 33

Sample Design 34

109

Sample Design 35

Sample Design 36
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H.

SAS Questionnaire Design

111

112

113

114

115

116

I.

Sample Survey Printout
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150
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J.

Input to SAS for ANOVA Analysis

DATA res1;
INPUT Subj (choose1-choose36)(1.) @@;
DATALINES;
1 113123332221323211321332313132332221
2 111123132222321211321312311122332121
3 121123331232223311321312311122332231
4 113123322222223221333132333132332221
5 113123132222333211123313313132332221
6 111123132223331311321322313133332321
7 313123331231221211123112321132313221
8 131123322223321221322133333132332131
9 111323331332223211113332321132331231
10 113123132222323212121312313122332121
11 111123332222131311323322313133132331
12 323323131112331311321312322321323121
13 113323132231223211122312311122231221
14 113123132232323212122312333122232221
15 113323121322323213132132312122311121
16 131123122211333321323131133133323133
17 113133331332111223112312222232111323
18 111123331232213211123312331122311221
19 113123332222323211322312313122331221
20 123123132223331311322312323122132221
21 211121322222223221333132313132332133
22 131123121222323221122113313132332131
23 113123131332323211121312311122332121
24 111123322222223212122332333131311211
25 113123131232323211122312311122312121
26 113313321332111213122312222212111223
27 111123332232223211333312333132311221
28 121123332223222321312123223223132333
29 113123132222321212321312333122232121
30 111123132222323212321312313132332221
31 111121131222223211323312313122332221
32 231121322232223221333133333132231133
33 111123131222223211123312311132312221
34 111123322222223221333332313132332233
35 113323321212323211131312311132331233
36 113123331232223211121312313122311121
37 111123322222221211323332313132332231
38 313122323231331213332132212223333332
39 123123132213111311122312322231133322
40 112323131332323212121312311122311221
41 133123132222322211323312333132232221
42 111123332222223211133332313132332131
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43 111123132222323211121312313132332121
44 113123332322323211323312313122232121
45 131313312212111211121131332131323211
46 123123332212211211133312323121332221
47 311123311332221321123132321222323212
48 113323332222323211321312313132332121
49 111121332222323211323312313132332121
50 131323131232233211321332311133312222
51 111323321232323211323312313122311123
52 113123131331323212121112331122211221
53 111123332222223221321312313132332133
;

DATA des1;
INPUT Set (x1-x13)(1.) @@;
DATALINES;
1 1321221211122
1 2312212111221
1 3222122121112
2 1311122212212
2 3212221221211
2 2122212212111
3 2321211122212
3 3122212212122
3 1111111111111
4 3321211122221
4 2211122212221
4 2322122121112
5 1212111222121
5 2321211122212
5 3212212111222
6 2111222122111
6 3212212111222
6 1321221211122
7 2122121112221
7 3222122121112
7 1321221211122
8 2221112221222
8 1312212111211
8 3122121112222
9 1111222122122
9 3312111222111
9 2221221211111
10 3212212111222
10 2321211122212
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10 1121112221221
11 2221221211111
11 2312111222122
11 1121112221221
12 2122212212111
12 1311122212212
12 2211111111122
13 1221211122212
13 1322122121121
13 2122121112221
14 1212111222121
14 2312212111221
14 3111111111112
15 1222121112211
15 2211111111122
15 3121112221211
16 2211122212221
16 2322122121112
16 3111111111112
17 3122121112222
17 1312212111211
17 2221112221222
18 3321221211121
18 2112221221212
18 1222212212112
19 1111222122122
19 2221112221222
19 3312111222111
20 1212111222121
20 2122121112221
20 3311122212212
21 2112221221212
21 1111111111111
21 3321211122221
22 2122212212111
22 3211222122121
22 1112221221222
23 1112221221222
23 2211111111122
23 3311122212212
24 3222122121112
24 1311122212212
24 2312212111221
25 3212221221211
25 1222212212112
25 2122121112221
26 2111222122111
26 1222121112211
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26 3122212212122
27 1111222122122
27 1222121112211
27 3312111222111
28 3321221211121
28 1221211122212
28 2211122212221
29 1222212212112
29 1111111111111
29 3321211122221
30 3212221221211
30 1322122121121
30 3111111111112
31 1212111222121
31 3122212212122
31 2322122121112
32 3121112221211
32 3211222122121
32 2312111222122
33 1121112221221
33 2312111222122
33 2221221211111
34 3311122212212
34 1322122121121
34 1221211122212
35 2221112221222
35 1112221221222
35 2111222122111
36 3122121112222
36 2221221211111
36 1312212111211
;

%mktmerge(design=des1, data=res1, out=resmer, nsets=36, nalts=3, setvars=choose1-choose36)

ods exclude notes mvanova anova;
proc transreg data=resmer utilities short separators= ', '
outtest=utils;
model identity(set:) = class(x1 x2 x3 x4 x5 x6 x7 x8 x9 x10 x11 x12 x13 / zero=sum);
weight c;
output p ireplace out=betas coefficients;
run;
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K.

MATLAB Script for maximizing SAS ANOVA Utility Functions

A=[1.1424
-1.455
0.3131
0.6135
0.2526
-0.8561
0.1558
-0.1558
0.6109
-0.6109
0.194
-0.194
-0.5734
0.5734
0.3427
-0.3427
-0.7739
0.7739
-0.9424
0.9424
-0.6502
0.6502
0.1283
-0.1286
0.4936
-0.4936
0.5877
-0.5877
A(:,5)=[
0.5292
-1.1462
0.6171
1.3988
-0.3001
-1.0987
0.4394
-0.4394
0.2335
-0.2335
0.2864
-0.2864
-0.7443
0.7443
-0.128
0.128
-0.4321
0.4321
-1.266
1.266
-0.8751
0.8751
0.1668
-0.1668
0.3364

1.2545
-1.4918
0.2372
0.8563
0.0916
-0.9476
0.0642
-0.0642
0.3546
-0.3546
0.1565
-0.1565
-0.4641
0.4641
0.2859
-0.2859
-0.7364
0.7364
-1.1304
1.1304
-0.6962
0.6962
0.0205
-0.0205
0.3763
-0.3763
0.4523
-0.4523

1.1599
-1.4442
0.2843
0.6717
0.1533
-0.825
0.2108
-0.2108
0.5341
-0.5341
0.2573
-0.2573
-0.608
0.608
0.33
-0.33
-0.8208
0.8208
-0.8774
0.8774
-0.6309
0.6309
0.1912
-0.1912
0.4957
-0.4957
0.5413
-0.5413

1.1272
-1.4558
0.3286
0.5742
0.286
-0.8602
0.1448
-0.1448
0.6589
-0.6589
0.1771
-0.1771
-0.5683
0.5683
0.3486
-0.3486
-0.7606
0.7606
-0.9496
0.9496
-0.6525
0.6525
0.1164
-0.1164
0.5036
-0.5036
0.6163
-0.6163];
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-0.3364
0.9325
-0.9325
];
for i=1:5
% i=2
z1=linspace(1,3,300);
x1=polyval(A(1:3,i),z1);
x2=polyval(A(4:6,i),z1);
plot(z1,x1,z1,x2)
z2=linspace(1,2,200);
x3=polyval(A(7:8,i),z2);
x4=polyval(A(9:10,i),z2);
x5=polyval(A(11:12,i),z2);
x6=polyval(A(13:14,i),z2);
x7=polyval(A(15:16,i),z2);
x8=polyval(A(17:18,i),z2);
x9=polyval(A(19:20,i),z2);
x10=polyval(A(21:22,i),z2);
x11=polyval(A(23:24,i),z2);
x12=polyval(A(25:26,i),z2);
x13=polyval(A(27:28,i),z2);
plot(z2,x3,z2,x4,z2,x5,z2,x6,z2,x7,z2,x8,z2,x9,z2,x10,z2,x11,z2,x12,z2,x13);
legend('x3','x4','x5','x6','x7','x8','x9','x10','x11','x12','x13')
xx(i,:)=[z1(find(max(x1)==x1))
z1(find(max(x2)==x2))
z2(find(max(x3)==x3))
z2(find(max(x4)==x4))
z2(find(max(x5)==x5))
z2(find(max(x6)==x6))
z2(find(max(x7)==x7))
z2(find(max(x8)==x8))
z2(find(max(x9)==x9))
z2(find(max(x10)==x10))
z2(find(max(x11)==x11))
z2(find(max(x12)==x12))
z2(find(max(x13)==x13))]';
end
%% Display the maximum of each utility function
xx

